Bicyclic propyl-based IL-17A modulators and uses thereof
The regulation of IL-17A by compounds of specific structures or their salts has solved the problems of malabsorption and high cost of existing IL-17A biologics, and effective treatment and cost reduction of inflammatory diseases have been achieved.
Patent Information
- Application Number
- CN202380035861.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-25
- Filing Date
- 2023-02-23
- Publication Date
- 2024-12-03
AI Technical Summary
Existing IL-17A biologics have malabsorption and high cost problems in the treatment of inflammatory diseases. Oral small molecule regulators lack effectiveness and are difficult to meet the treatment needs.
Provided is a compound of a specific structure or a pharmaceutically acceptable salt thereof for regulating IL-17A in an individual for the treatment of inflammatory diseases such as psoriasis, ankylosing spondylitis, etc., administered by oral routes of administration to Improve treatment efficiency and reduce costs.
It has achieved effective regulation of IL-17A, improved the treatment effect of inflammatory diseases, reduced the treatment cost, and provided a more convenient and economical treatment plan.
Smart Images

Figure CN119072465A_ABST
Abstract
Description
[0001] Cross-references
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 314,257, filed on February 25, 2022, which is incorporated herein by reference in its entirety. Background Art
[0003] The IL-17 family consists of six cytokines (IL-17A to IL-17F). Interleukin-17A (IL-17A) is a defined proinflammatory cytokine that is involved in inducing IL-6, IL-8, G-CSF, TNF-α, IL-1β, PGE2 and IFN-γ as well as numerous chemokines and other effectors. IL-17A can form homodimers or heterodimers with its family member IL-17F, and can bind to two IL-17 receptors IL-17RA and IL-17RC to mediate signal transduction. IL-17A is a major pathological cytokine expressed by Th17 cells, involved in the pathology of inflammation and autoimmunity, and also expressed by CD8+T cells, γδ cells, NK cells, NKT cells, macrophages and dendritic cells. In addition, although IL-17A and Th17 are involved in inflammation and autoimmune disorders, they are essential for defense against various microorganisms. In addition, IL-17A can synergize with other inflammatory cytokines such as TNF-α, IFN-γ, and IL-1β to mediate proinflammatory effects.
[0004] To date, a few biologics (Secukinumab and Ixekizumab) have been approved to modulate IL-17A for the treatment of inflammatory diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis. These treatments require injections to patients because they are not easily absorbed by the intestine when taken orally. In addition, these approved biologic treatments have a high cost of entry for patients, limiting their availability to patient populations in need. A few IL-17A small molecule modulators have been approved for oral administration. However, despite the convenience of oral administration and lower cost of entry for patients, these small molecule modulators lack the efficacy of approved biologics. Therefore, there is a need to develop powerful small molecule IL-17A modulators for the treatment of inflammatory diseases and other related disorders. Summary of the invention
[0005] In certain aspects, the present disclosure provides a compound represented by the structure of formula (I):
[0006]
[0007] or a pharmaceutically acceptable salt thereof, wherein:
[0008] A is selected from C3-6 carbocycle and 5 to 6 membered heterocycle, any of which is optionally substituted by one or more substituents independently selected from (a), (b) and (c):
[0009] (a) Halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN;
[0010] (b) C optionally substituted by one or more substituents 1-6 Alkyl, the substituents are independently selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 、-NO2、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and
[0011] (c) C optionally substituted by one or more substituents 3-6 Carbocyclic ring, the substituents are independently selected from: halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN;
[0012] R 1 Selected from hydrogen, halogen, -OR 12 、-N(R 12 )2. -C(O)R 12 、-C(O)OR 12 , -NO2, -CN, and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 12 、-N(R 12 )2. -C(O)R 12 、-C(O)OR 12 , -NO2 and -CN;
[0013] R 2 Selected from -N(R A )C(O)(R B ) and -N(R C )C(O)N(R D )(R E );
[0014] is selected from a 4 to 12 membered heterocyclic ring optionally substituted by one or more substituents independently selected from:
[0015] Halogen, -OR 13 、-N(R 13 )2. -C(O)R 13 、-C(O)OR 13 , -NO2, -CN, and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2. -C(O)R 13 、-C(O)OR 13 , -NO2 and -CN;
[0016] R 3 Selected from halogen, -OR 14 、-N(R 14 )2. -C(O)R 14 、-C(O)OR 14 、-NO2、-CN、C 1-6 Alkyl and C 3-6 A carbon ring, in which each C 1-6 Alkyl and C 3-6 The carbocyclic ring is optionally substituted with one or more substituents independently selected from halogen, -OR 14 、-N(R 14 )2. -C(O)R 14 、-C(O)OR 14 , -NO2 and -CN;
[0017] R A Selected from hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 15 、-N(R 15 )2. -C(O)R 15 、-C(O)OR 15 , -NO2 and -CN;
[0018] R B Selected from:
[0019] C optionally substituted by one or more substituents 1-6 Alkyl, the substituents are independently selected from:
[0020] Halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 , -NO2, -CN;
[0021] C 3-6 carbocyclic and 5- to 6-membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 ,
[0022] -C(O)OR 16 , -NO2 and -CN; and
[0023] C 3-6 A carbocyclic ring or a 4- to 6-membered heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from:
[0024] Halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and
[0025] -CN;
[0026] R C Selected from hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR17 , -NO2 and -CN; R D Selected from C 1-6 Alkyl and C 3-6 carbocyclic ring, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 , -NO2 and -CN;
[0027] R E Selected from hydrogen, C 1-6 Alkyl and C 3-6 carbocyclic ring, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 19 、-N(R 19 )2. -C(O)R 19 、-C(O)OR 19 , -NO2 and -CN;
[0028] R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 Each occurrence is independently selected from:
[0029] hydrogen;
[0030] C optionally substituted by one or more substituents 1-6 Alkyl, the substituents are independently selected from: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN; and
[0031] C optionally substituted by one or more substituents 3-10 Carbocyclic rings and 3 to 10 membered heterocyclic rings, the substituents being independently selected from: halogen, -OH, -OC 1-6 Alkyl, -OC 1-6Haloalkyl, -NH2, -NO2, =O and -CN; and
[0032] n is selected from 0, 1, 2, 3 and 4.
[0033] In certain embodiments, the present disclosure provides a pharmaceutical composition comprising a compound or salt of formula (I) and a pharmaceutically acceptable excipient.
[0034] In certain aspects, the disclosure provides a method of modulating IL-17A in an individual in need thereof, the method comprising administering to the individual a compound or salt of Formula (I), or a pharmaceutical composition thereof.
[0035] In certain aspects, the present disclosure provides a method for treating an inflammatory disease or condition, the method comprising administering a compound or salt of formula (I) to an individual, or a pharmaceutical composition thereof. In some embodiments, the inflammatory disease or condition is selected from plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, psoriatic arthritis, ankylosing spondylitis, suppurative hidradenitis, rheumatoid arthritis, palmoplantar psoriasis, spondyloarthritis, and non-infectious uveitis.
[0036] Incorporation by reference
[0037] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. If publications and patents or patent applications incorporated by reference conflict with the disclosure contained in the specification, the specification is intended to supersede and / or take precedence over any such conflicting content. DETAILED DESCRIPTION OF THE INVENTION
[0039] Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Without departing from the present invention, those skilled in the art will appreciate that numerous changes, variations and substitutions will be appreciated. It should be understood that the various alternatives of the embodiments of the present invention described herein can be used to practice the present invention. The following claims are intended to define the scope of the present invention, and are therefore intended to encompass methods and structures within the scope of these claims and their equivalents.
[0040] definition
[0041] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications mentioned herein are incorporated herein by reference.
[0042] As used in the specification and claims, the singular form "a," "an," and "the" include plural references unless the context clearly dictates otherwise.
[0043] "Alkyl" refers to a straight or branched hydrocarbon chain monovalent group consisting only of carbon and hydrogen atoms, containing no unsaturation, and preferably having from one to twelve carbon atoms (i.e., C1-C 12 The alkyl group is connected to the rest of the molecule by a single bond. In certain embodiments, the alkyl group contains from one to twelve carbon atoms (i.e., C1-C 12 In certain embodiments, the alkyl group comprises one to eight carbon atoms (i.e., C1-C8 alkyl). In other embodiments, the alkyl group comprises one to five carbon atoms (i.e., C1-C5 alkyl). In other embodiments, the alkyl group comprises one to four carbon atoms (i.e., C1-C4 alkyl). In other embodiments, the alkyl group comprises one to three carbon atoms (i.e., C1-C3 alkyl). In other embodiments, the alkyl group comprises one to two carbon atoms (i.e., C1-C2 alkyl). In other embodiments, the alkyl group comprises one carbon atom (i.e., C1 alkyl). In other embodiments, the alkyl group comprises five to fifteen carbon atoms (i.e., C5-C 15 In some embodiments, the alkyl group may be a methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (isopropyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl), etc.
[0044] "Alkenyl" refers to a straight or branched hydrocarbon chain radical (i.e., C2-C 12In some embodiments, the alkenyl group comprises two to eight carbon atoms (i.e., C2-C8 alkenyl). In some embodiments, the alkenyl group comprises two to six carbon atoms (i.e., C2-C6 alkenyl). In other embodiments, the alkenyl group comprises two to four carbon atoms (i.e., C2-C4 alkenyl). The alkenyl group is connected to the rest of the molecule by a single bond, such as ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, pent-1,4-dienyl, etc.
[0045] "Alkynyl" refers to a straight or branched hydrocarbon chain radical (i.e., C2-C 12 In some embodiments, the alkynyl group comprises two to eight carbon atoms (i.e., C2-C8 alkynyl). In other embodiments, the alkynyl group comprises two to six carbon atoms (i.e., C2-C6 alkynyl). In other embodiments, the alkynyl group comprises two to four carbon atoms (i.e., C2-C4 alkynyl). The alkynyl group is connected to the rest of the molecule by a single bond, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc.
[0046] "Alkylene" refers to a straight divalent hydrocarbon chain that connects the rest of the molecule to a radical, consisting only of carbon and hydrogen, containing no unsaturation, and preferably having one to twelve carbon atoms, such as methylene, ethylene, propylene, butylene, etc. The alkylene chain is connected to the rest of the molecule by a single bond, and to the radical by a single bond. The connection points of the alkylene chain to the rest of the molecule and to the radical are reached by terminal carbons, respectively. The alkylene chain may be optionally substituted with one or more substituents such as those described herein. In certain embodiments, the alkylene group comprises one to ten carbon atoms (i.e., C1-C 10 In certain embodiments, the alkylene group comprises one to eight carbon atoms (i.e., C1-C8 alkylene). In other embodiments, the alkylene group comprises one to five carbon atoms (i.e., C1-C5 alkylene). In other embodiments, the alkylene group comprises one to four carbon atoms (i.e., C1-C4 alkylene). In other embodiments, the alkylene group comprises one to three carbon atoms (i.e., C1-C3 alkylene). In other embodiments, the alkylene group comprises one to two carbon atoms (i.e., C1-C2 alkylene). In other embodiments, the alkylene group comprises one carbon atom (i.e., C1 alkylene). In other embodiments, the alkylene group comprises five to eight carbon atoms (i.e., C5-C8 alkylene). In other embodiments, the alkylene group comprises two to five carbon atoms (i.e., C2-C5 alkylene). In other embodiments, the alkylene group comprises three to five carbon atoms (i.e., C3-C5 alkylene).
[0047] "Alkenylene" refers to a straight divalent hydrocarbon chain that connects the rest of the molecule to a radical, consisting only of carbon and hydrogen, containing at least one carbon-carbon double bond, and preferably having two to twelve carbon atoms. The alkenylene chain is connected to the rest of the molecule by a single bond, and to the radical by a single bond. The connection points of the alkenylene chain to the rest of the molecule and to the radical are reached through the terminal carbon, respectively. The alkenylene chain may be optionally substituted with one or more substituents such as those described herein. In certain embodiments, the alkenylene group comprises two to ten carbon atoms (i.e., C2-C 10 In certain embodiments, the alkenylene group comprises two to eight carbon atoms (i.e., C2-C8 alkenylene). In other embodiments, the alkenylene group comprises two to five carbon atoms (i.e., C2-C5 alkenylene). In other embodiments, the alkenylene group comprises two to four carbon atoms (i.e., C2-C4 alkenylene). In other embodiments, the alkenylene group comprises two to three carbon atoms (i.e., C2-C3 alkenylene). In other embodiments, the alkenylene group comprises two carbon atoms (i.e., C2 alkenylene). In other embodiments, the alkenylene group comprises five to eight carbon atoms (i.e., C5-C8 alkenylene). In other embodiments, the alkenylene group comprises three to five carbon atoms (i.e., C3-C5 alkenylene).
[0048] "Alkynylidene" refers to a straight divalent hydrocarbon chain that connects the rest of the molecule to a radical, consisting only of carbon and hydrogen, containing at least one carbon-carbon triple bond, and preferably having two to twelve carbon atoms. The alkynylene chain is connected to the rest of the molecule by a single bond, and to the radical by a single bond. The points of connection of the alkynylene chain to the rest of the molecule and to the radical are respectively reached through the terminal carbon. The alkynylene chain may be optionally substituted with one or more substituents such as those described herein. In certain embodiments, the alkynylene group comprises two to ten carbon atoms (i.e., C2-C 10 In certain embodiments, the alkynylene group comprises two to eight carbon atoms (i.e., C2-C8 alkynylene). In other embodiments, the alkynylene group comprises two to five carbon atoms (i.e., C2-C5 alkynylene). In other embodiments, the alkynylene group comprises two to four carbon atoms (i.e., C2-C4 alkynylene). In other embodiments, the alkynylene group comprises two to three carbon atoms (i.e., C2-C3 alkynylene). In other embodiments, the alkynylene group comprises two carbon atoms (i.e., C2 alkynylene). In other embodiments, the alkynylene group comprises five to eight carbon atoms (i.e., C5-C8 alkynylene). In other embodiments, the alkynylene group comprises three to five carbon atoms (i.e., C3-C5 alkynylene).
[0049] The term "C x-y " when used in conjunction with a chemical moiety such as alkyl, alkenyl, or alkynyl is intended to include groups containing from x to y carbons in the chain. For example, the term "C1-6 "Alkyl" refers to a substituted or unsubstituted saturated hydrocarbon group containing 1 to 6 carbon atoms, including straight-chain alkyl and branched-chain alkyl. The term -C x-y Alkylene- refers to a substituted or unsubstituted alkylene chain having from x to y carbons in the alkylene chain. For example, -C 1-6 Alkylene- may be selected from methylene, ethylene, propylene, butylene, pentylene and hexylene, any of which is optionally substituted.
[0050] The term "C x-y "Alkenyl" and "C x-y "Alkynyl" refers to an unsaturated aliphatic group analogous to the alkyl groups described above in length and possible substitution, but containing at least one double or triple bond, respectively. The term -C x-y Alkenylene- refers to a substituted or unsubstituted alkenylene chain having from x to y carbons in the alkenylene chain. For example, -C 2-6 Alkenylene- may be selected from vinylene, propenylene, butenylene, pentenylene and hexenylene, any of which is optionally substituted. The alkenylene chain may have one double bond or more than one double bond in the alkenylene chain. x-y Alkyne- refers to a substituted or unsubstituted alkynylene chain having from x to y carbons in the alkynylene chain. For example, -C 2-6 Alkyne- may be selected from ethynylene, propynylene, butynylene, pentynylene and hexynylene, any of which is optionally substituted. The alkynylene chain may have one triple bond or more than one triple bond in the alkynylene chain.
[0051] As used herein, the term "carbocycle" refers to a saturated, unsaturated or aromatic ring, wherein each atom of the ring is carbon. Carbocycles include 3 to 10-membered monocycles and 6 to 12-membered bicyclic rings. Each ring of a bicyclic carbocycle can be selected from saturated, unsaturated and aromatic rings. Bicyclic carbocycles can be fused, bridged or spirocyclic systems. In some embodiments, the carbocycle is an aryl group. In some embodiments, the carbocycle is a cycloalkyl group. In some embodiments, the carbocycle is a cycloalkenyl group. In an exemplary embodiment, an aromatic ring such as a phenyl group can be fused to a saturated or unsaturated ring such as cyclohexane, cyclopentane or cyclohexene. Where valence permits, any combination of saturated, unsaturated and aromatic bicyclic rings is included in the definition of carbocycles. Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl and naphthyl. The carbocycle can be optionally substituted with one or more substituents such as those described herein.
[0052] "Cycloalkyl" refers to a stable, fully saturated monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, including fused or bridged ring systems, and preferably having three to twelve carbon atoms (i.e., C 3-12In certain embodiments, the cycloalkyl group contains three to ten carbon atoms (i.e., C 3-10 In other embodiments, the cycloalkyl group contains five to seven carbon atoms (i.e., C 5-7 Cycloalkyl). The cycloalkyl group may be attached to the rest of the molecule by a single bond. Examples of monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl groups include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl, and the like. The cycloalkyl group may be optionally substituted with one or more substituents such as those described herein.
[0053] "Cycloalkenyl" refers to a stable, unsaturated, non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, including fused or bridged ring systems, preferably having three to twelve carbon atoms, and containing at least one double bond (i.e., C 3-12 In certain embodiments, the cycloalkenyl group contains three to ten carbon atoms (i.e., C 3-10 In other embodiments, the cycloalkenyl group contains five to seven carbon atoms (i.e., C 5-7 Cycloalkenyl). The cycloalkenyl group may be attached to the rest of the molecule by a single bond. Examples of monocyclic cycloalkenyl groups include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. The cycloalkenyl group may be optionally substituted with one or more substituents such as those described herein.
[0054] "Aryl" refers to a radical derived from an aromatic monocyclic or polycyclic hydrocarbon ring system by removing hydrogen atoms from ring carbon atoms. The aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and carbon and consists of five to eighteen carbon atoms, wherein at least one ring in the ring system is aromatic, i.e., it contains a cyclic delocalized (4n+2) π electron system that conforms to the Hückel theory. The ring systems from which aryl groups are derived include, but are not limited to, radicals such as benzene, fluorene, indane, indene, tetralin and naphthalene. Aryl groups may be optionally substituted with one or more substituents such as those described herein.
[0055] “C x-y "Carbocycle" is intended to include groups containing x to y carbons in the ring. For example, the term "C 3-6 A "carbocycle" may be a saturated, unsaturated or aromatic ring system containing 3 to 6 carbon atoms, any of which are optionally substituted as provided herein.
[0056] As used herein, the term "heterocycle" refers to a saturated, unsaturated, non-aromatic or aromatic ring containing one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B and S atoms. Heterocycles include 3 to 10-membered monocycles and 6 to 12-membered bicyclic rings. Each ring of the bicyclic heterocycle can be selected from saturated, unsaturated and aromatic rings. In some embodiments, the heterocycle includes at least one heteroatom selected from oxygen, nitrogen, sulfur or any combination thereof. In some embodiments, the heterocycle includes at least one heteroatom selected from oxygen, nitrogen or any combination thereof. In some embodiments, the heterocycle includes at least one heteroatom selected from oxygen, sulfur or any combination thereof. In some embodiments, the heterocycle includes at least one heteroatom selected from nitrogen, sulfur or any combination thereof. In some embodiments, the heterocycle includes at least one heteroatom selected from nitrogen, sulfur or any combination thereof. Where valence permits, the heterocycle can be connected to the rest of the molecule by any atom of the heterocycle such as a carbon or nitrogen atom of the heterocycle. In some embodiments, the heterocycle is a heteroaryl. In some embodiments, the heterocycle is a heterocycloalkyl. Exemplary heterocycles include pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, oxazolyl, thiazolyl, morpholinyl, indazolyl, indolyl and quinolyl. The heterocycle may be optionally substituted with one or more substituents such as those described herein. The bicyclic heterocycle may be fused, bridged or spirocyclic system. In an exemplary embodiment, heterocycles such as pyridyl may be fused to saturated or unsaturated rings such as cyclohexane, cyclopentane or cyclohexene. The heterocycle may be optionally substituted with one or more substituents such as those described herein.
[0057] "Heterocycloalkyl" refers to a stable 3 to 12-membered non-aromatic ring group comprising two to twelve carbon atoms and at least one heteroatom, wherein each heteroatom may be selected from N, O, Si, P, B and S atoms. In some embodiments, heterocycloalkyl comprises at least one heteroatom selected from oxygen, nitrogen, sulfur or any combination thereof. In some embodiments, heterocycloalkyl comprises at least one heteroatom selected from oxygen, nitrogen or any combination thereof. In some embodiments, heterocycloalkyl comprises at least one heteroatom selected from oxygen, sulfur or any combination thereof. In some embodiments, heterocycloalkyl comprises at least one heteroatom selected from nitrogen, sulfur or any combination thereof. Heterocycloalkyl may be selected from monocyclic or bicyclic and fused or bridged ring systems. The heteroatoms in heterocycloalkyl are optionally oxidized. If present, one or more nitrogen atoms are optionally quaternized. Heterocycloalkyl is partially or completely saturated. Where valence permits, heterocycloalkyl is connected to the remainder of the molecule by any atom of heterocycloalkyl such as any carbon or nitrogen atom of heterocycloalkyl. Examples of heterocycloalkyl include, but are not limited to, dioxolane, thienyl [1,3] dithiane, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Heterocycloalkyl may be optionally substituted with one or more substituents such as those described herein.
[0058] The term "heteroaryl" refers to a group derived from a 3 to 12-membered aromatic ring group, which includes one to eleven carbon atoms and at least one heteroatom, wherein each heteroatom can be selected from N, O and S. In some embodiments, the heteroaryl group includes at least one heteroatom selected from oxygen, nitrogen, sulfur or any combination thereof. In some embodiments, the heteroaryl group includes at least one heteroatom selected from oxygen, nitrogen or any combination thereof. In some embodiments, the heteroaryl group includes at least one heteroatom selected from oxygen, sulfur or any combination thereof. In some embodiments, the heteroaryl group includes at least one heteroatom selected from nitrogen, sulfur or any combination thereof. As used herein, the heteroaryl ring can be selected from a monocyclic or bicyclic and fused or bridged ring system ring, wherein at least one ring in the ring system is aromatic, i.e., it contains a cyclic delocalized (4n+2) π electron system that conforms to the Huckel theory. One or more heteroatoms in the heteroaryl group may be optionally oxidized. If present, one or more nitrogen atoms are optionally quaternized. Where valence permits, the heteroaryl group may be attached to the remainder of the molecule through any atom of the heteroaryl group, such as a carbon or nitrogen atom of the heteroaryl group. "Heteroaryl" includes an aromatic monocyclic ring structure whose ring structure includes at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms, preferably a 5-6 membered ring. Heteroaryl includes, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine. The heteroaryl group may be optionally substituted with one or more substituents, such as those described herein. "Heteroaryl" also includes a polycyclic ring system with two or more rings, wherein two or more atoms are shared by two adjacent rings, wherein at least one ring is heteroaromatic, for example, the other rings may be aromatic or non-aromatic carbocyclic or heterocyclic. The heteroaryl group may be optionally substituted with one or more substituents, such as those described herein.
[0059] "X-membered heterocycle" refers to the number of intracyclic atoms in the ring, ie, X. For example, a 5-membered heteroaryl ring or a 5-membered aromatic heterocycle has 5 intracyclic atoms, such as triazole, oxazole, thiophene, and the like.
[0060] "Alkoxy" refers to a group bonded through an oxygen atom of the formula -O-alkyl, wherein alkyl is an alkyl chain as defined above.
[0061] "Halo" or "halogen" refers to a halogen substituent such as bromo, chloro, fluoro, and iodo substituents.
[0062] As used herein, the term "haloalkyl" or "haloalkane" refers to an alkyl group as defined above substituted with one or more halogen groups, for example, trifluoromethyl, dichloromethyl, bromomethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. In some embodiments, the alkyl portion of the fluoroalkyl group is optionally further substituted. Examples of halogen-substituted alkanes ("haloalkanes") include halogenated methane (e.g., chloromethane, bromomethane, fluoromethane, iodomethane), dihalogenated methane and trihalogenated methane (e.g., chloroform, bromoform, trifluoromethane, iodoform), 1-haloethane, 2-haloethane, 1,2-dihaloethane, 1-halopropane, 2-halopropane, 3-halopropane, 1,2-dihalopropane, 1,3-dihalopropane, 2,3-dihalopropane, 1,2,3-trihalopropane, and any other suitable combination of an alkane (or substituted alkane) and a halogen (e.g., Cl, Br, F, and I). When an alkyl group is substituted with more than one halogen group, each halogen may be independently selected, such as 1-chloro, 2-fluoroethane.
[0063] The term "substituted" refers to the part of replacing hydrogen with a substituent on one or more carbons or replaceable heteroatoms such as NH or NH2 of a compound. It should be understood that "substituted" or "substituted by..." includes implicit conditions, i.e., such substitutions meet the allowed valences of the substituted atoms and substituents, and the substitutions produce stable compounds, i.e., compounds that do not spontaneously undergo transformations such as by rearrangement, cyclization, elimination, etc. In certain embodiments, substituted refers to the part where two hydrogen atoms on the same carbon atom are replaced by substituents, such as replacing two hydrogen atoms on a single carbon with oxo, imino or thio. As used herein, the term "substituted" is considered to include all permissible substituents of organic compounds. In a broad sense, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. For appropriate organic compounds, permissible substituents may be one or more, and may be the same or different.
[0064] In some embodiments, the substituents may include any of the substituents described herein, for example, halogen, hydroxyl, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a )2. -R b -N(R a )2. -Rb -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (wherein t is 1 or 2); and alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl, any of which may be optionally substituted by alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a )2. -R b -ORc -C(O)N(R a )2. -R b -N(R a )C(O)OR a , -R b -N(R a )C(O)R a , -R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2); where each R a is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroarylalkyl, wherein each R a Where valence permits, it may be optionally substituted by: alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a , -R b-N(R a )C(O)R a , -R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2); and where each R b are independently selected from a direct bond or a straight or branched alkylene, alkenylene or alkynylene chain, and each R c is a straight or branched alkylene, alkenylene or alkynylene chain. It will be appreciated by those skilled in the art that substituents may themselves be substituted if appropriate.
[0065] The term "salt" or "pharmaceutically acceptable salt" refers to salts derived from a variety of organic and inorganic counterions well known in the art. Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
[0066] The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0067] As used herein, the phrase "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
[0068] The terms "subject," "individual," and "patient" are used interchangeably and refer to humans as well as non-human mammals (e.g., non-human primates, canines, equines, felines, porcines, bovines, ungulates, lagomorphs, etc.). In various embodiments, an individual may be a person (e.g., an adult male, an adult female, an adolescent male, an adolescent female, a male child, a female child) who is under the care of a physician or other health care provider in a hospital, as an outpatient, or in other clinical settings. In certain embodiments, an individual may not be under the care or prescription of a physician or other health care provider.
[0069] As used herein, the phrase "subject in need thereof" refers to an individual as described below who suffers from, or is at risk of, a condition to be treated prophylactically or therapeutically with a compound or salt described herein.
[0070] The term "administering" is defined as providing a composition to an individual by a route known in the art, including but not limited to intravenous, intraarterial, oral, parenteral, buccal, topical, transdermal, rectal, intramuscular, subcutaneous, intraosseous, transmucosal or intraperitoneal administration routes. In certain embodiments, an oral route of administering the composition may be used. The term "administering" a compound should be understood to mean providing a compound of the invention or a salt of a compound of the invention to an individual in need thereof.
[0071] As used herein, "treatment" refers to a method for obtaining a beneficial or desired result about a disease, disorder or medical condition, including but not limited to a therapeutic benefit and / or a preventive benefit. In certain embodiments, treatment involves administering a compound or composition disclosed herein to an individual. The therapeutic benefit may include the eradication or improvement of the underlying disorder being treated. In addition, the therapeutic benefit may be achieved by eradicating or improving one or more physiological symptoms associated with the underlying disorder, such as by observing improvements in the individual, even though the individual may still be afflicted with the underlying disorder. In certain embodiments, for preventive benefits, the composition is administered to an individual at risk of developing a specific disease, or an individual reporting one or more physiological symptoms of the disease, although the disease may not yet be diagnosed. Treatment may include, for example, reducing, delaying or alleviating the severity of one or more symptoms of a disease or disorder, or it may include reducing the frequency of symptoms of a patient experiencing a disease, defect, disorder or adverse condition, etc. Treatment may be used herein to refer to a method that results in a certain level of treatment or improvement of a disease or disorder, and may cover a range of results directed to that purpose, including but not limited to preventing the disorder completely.
[0072] In certain embodiments, the term "prevent" or "preventing" as it relates to a disease or condition may mean that in a statistical sample, a compound reduces the occurrence of the disorder or condition in treated samples relative to untreated control samples, or delays the onset of or reduces the severity of one or more symptoms of the disorder or condition relative to untreated control samples.
[0073] The terms "inhibit," "selective inhibition," or "selectively inhibit" refer to the ability of an agent (chemical or biological) to preferentially reduce target signaling activity over off-target signaling activity through direct or indirect interaction with the target.
[0074] As used herein, "therapeutic effect" encompasses therapeutic benefit and / or prophylactic benefit as described above. Prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, stopping or reversing the progression of a disease or condition, or any combination thereof.
[0075] Compound
[0076] In some aspects, the present disclosure provides a compound represented by the structure of formula (I):
[0077]
[0078] or a pharmaceutically acceptable salt thereof, wherein:
[0079] A is selected from C 3-6 carbocyclic ring and 5- to 6-membered heterocyclic ring, any of which is optionally substituted by one or more substituents,
[0080] The substituents are independently selected from (a), (b) and (c):
[0081] (a) Halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN;
[0082] (b)C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 、-NO2、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from halogen, -OR11 、-N(R 11 )2.
[0083] -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and
[0084] (c)C 3-6 Carbon ring, the C 3-6 The carbocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN;
[0085] R 1 Selected from hydrogen, halogen, -OR 12 、-N(R 12 )2. -C(O)R 12 、-C(O)OR 12 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 12 、-N(R 12 )2. -C(O)R 12 、-C(O)OR 12 , -NO2 and -CN;
[0086] R 2 Selected from -N(R A )C(O)(R B ) and -N(R C )C(O)N(R D )(R E );
[0087] is selected from a 4- to 12-membered heterocyclic ring, the 4- to 12-membered heterocyclic ring being optionally substituted with one or more substituents independently selected from:
[0088] Halogen, -OR 13 、-N(R 13 )2. -C(O)R 13 、-C(O)OR 13 , -NO2, -CN, and C 1-6 Alkyl, the C 1-6The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2. -C(O)R 13 、-C(O)OR 13 , -NO2 and -CN;
[0089] R 3 Selected from halogen, -OR 14 、-N(R 14 )2. -C(O)R 14 、-C(O)OR 14 、-NO2、-CN、C 1-6 Alkyl and C 3-6 A carbon ring, in which each C 1-6 Alkyl and C 3-6 The carbocyclic ring is optionally substituted with one or more substituents independently selected from halogen, -OR 14 、-N(R 14 )2. -C(O)R 14 、-C(O)OR 14 , -NO2 and -CN;
[0090] R A Selected from hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 15 、-N(R 15 )2. -C(O)R 15 、-C(O)OR 15 , -NO2 and -CN; R B Selected from:
[0091] C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted with one or more substituents independently selected from:
[0092] Halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 ,
[0093] -NO2, -CN;
[0094] C 3-6 carbocyclic and 5- to 6-membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR16 、-N(R 16 )2. -C(O)R 16 ,
[0095] -C(O)OR 16 , -NO2 and -CN; and
[0096] C 3-6 A carbocyclic ring or a 4- to 6-membered heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from:
[0097] Halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and
[0098] -CN;
[0099] R C Selected from hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 , -NO2 and -CN;
[0100] R D Selected from C 1-6 Alkyl and C 3-6 carbocyclic ring, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 , -NO2 and -CN;
[0101] R E Selected from hydrogen, C 1-6 Alkyl and C 3-6 carbocyclic ring, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 19、-N(R 19 )2. -C(O)R 19 、-C(O)OR 19 , -NO2 and -CN;
[0102] R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 Each occurrence is independently selected from:
[0103] hydrogen;
[0104] C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN; and
[0105] C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN; and
[0106] n is selected from 0, 1, 2, 3 and 4.
[0107] In some embodiments, for the compound or salt of Formula (I), n is selected from 0, 1, 2, and 3. In some embodiments, n is selected from 0, 1, and 2. In some embodiments, n is selected from 0 and 1. In some embodiments, n is selected from 1, 2, 3, and 4. In some embodiments, n is selected from 2, 3, and 4. In some embodiments, n is selected from 3 and 4. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4.
[0108] In some embodiments, for compounds or salts of Formula (I), each R3 are independently selected from halogen, -OR 14 、-N(R 14 )2. -C(O)R 14 、-C(O)OR 14 , -NO2 and -CN. In some embodiments, each R 3 are independently selected from halogen, -OR 14 , -NO2 and -CN. In some embodiments, each R 3 are independently selected from chlorine, fluorine, bromine and -OR 14 In some embodiments, each R 3 is independently selected from chlorine, fluorine and bromine. 3 In some embodiments, each R 3 It's fluorine.
[0109] In some embodiments, for compounds or salts of Formula (I), each R 3 Selected from C 1-6 Alkyl and C 3-6 A carbon ring, in which each C 1-6 Alkyl and C 3-6 The carbocyclic ring is optionally substituted with one or more substituents independently selected from halogen, -OR 14 、-N(R 14 )2. -C(O)R 14 、-C(O)OR 14 , -NO2 and -CN. In some embodiments, each R 3 is selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 14 、-N(R 14 )2. -C(O)R 14 、-C(O)OR 14 , -NO2 and -CN.
[0110] In some embodiments, for compounds or salts of Formula (I), each R 3 are independently selected from halogen, -OR 14 、-N(R 14 )2.-CN, C 1-3 Alkyl, C 1-3 haloalkyl and optionally substituted C 3-6 In some embodiments, each R 3 are independently selected from halogen, -OR 14 、-N(R 14)2, -CN, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In some embodiments, each R 3 are independently selected from halogen, -OR 14 、-N(R 14 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, each R 3 are independently selected from fluorine, chlorine, -OR 14 、-N(R 14 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, each R 3 are independently selected from fluorine, chlorine, -OR 14 、-N(R 14 )2 and -CN. In some embodiments, each R 3 In some embodiments, each R 3 Selected from fluorine.
[0111] In some embodiments, for compounds or salts of Formula (I), n is selected from 1, 2, and 3; and each R 3 are independently selected from halogen, -OR 14 、-N(R 14 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, n is selected from 1, 2, and 3; and each R 3 are independently selected from fluorine, chlorine, -OR 14 、-N(R 14 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, n is selected from 1, 2, and 3; and each R 3 Selected from fluorine.
[0112] In some embodiments, for the compound or salt of Formula (I), n is 1; and R 3 are independently selected from halogen, -OR 14 、-N(R 14 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, n is 1; and R 3 are independently selected from fluorine, chlorine, -OR 14 、-N(R 14 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, n is 1; and R3 Selected from fluorine.
[0113] In some embodiments, for the compound or salt of Formula (I) or (IA), R 1 Selected from hydrogen, halogen, -OR 12 、-N(R 12 )2. -C(O)R 12 、-C(O)OR 12 , -NO2 and -CN. In some embodiments, R 1 Selected from halogen, -OR 12 、-N(R 12 )2. -C(O)R 12 、-C(O)OR 12 , -NO2 and -CN. In some embodiments, R 1 Selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 12 、-N(R 12 )2. -C(O)R 12 、-C(O)OR 12 , -NO2 and -CN. In some embodiments, R 1 Selected from hydrogen, halogen, -OR 12 、-N(R 12 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, R 1 Selected from halogen, -OR 12 、-N(R 12 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, R 1 is selected from methyl, ethyl, propyl and isopropyl, any of which is optionally substituted by halogen, -OR 12 、-N(R 12 )2 and -CN are substituted. In some embodiments, R 1 is selected from the group consisting of methyl, ethyl, propyl, isopropyl and trifluoromethyl. 1 is selected from the group consisting of methyl, ethyl, propyl and isopropyl. 1 is selected from methyl and trifluoromethyl. 1 In some embodiments, R 1 Selected from trifluoromethyl.
[0114] In some embodiments, for compounds or salts of Formula (I) or (IA), A is selected from saturated C 3-6 carbocyclic and 5-membered heteroaryl, any of which is optionally substituted with one or more substituents independently selected from: (a), (b) and (c):
[0115] (a) Halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN;
[0116] (b)C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 、-NO2、-CN、C 3-6 Carbocyclic and 5- to 6-membered heterocyclic rings, each C 3-6 The carbocyclic and 5- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2.
[0117] -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and
[0118] (c)C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0119] In some embodiments, for compounds or salts of Formula (I) or (IA), A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrazole, imidazole, oxazole, isoxazole, oxadiazole, triazole, and tetrazole, any of which is optionally substituted with one or more substituents independently selected from: (a), (b), and (c):
[0120] (a) Halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11, -NO2 and -CN;
[0121] (b)C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 、-NO2、-CN、C 3-6 Carbocyclic and 5- to 6-membered heterocyclic rings, each C 3-6 The carbocyclic and 5- to 6-membered heterocyclic rings are optionally substituted by one or more substituents. The substituents are independently selected from: halogen, -OR 11 、-N(R 11 )2.
[0122] -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and
[0123] (c)C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0124] In some embodiments, for compounds or salts of Formula (I) or (IA), A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and phenyl, any of which is optionally substituted with one or more substituents independently selected from: (a), (b), and (c):
[0125] (a) Halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN;
[0126] (b)C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 、-NO2、
[0127] -CN、C 3-6Carbocyclic and 5- to 6-membered heterocyclic rings, each C 3-6 The carbocyclic and 5- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 11 ,
[0128] -N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and
[0129] (c)C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0130] In some embodiments, for compounds or salts of Formula (I) or (IA), A is selected from pyrazole, imidazole, oxazole, isoxazole, oxadiazole, triazole, and tetrazole, any of which is optionally substituted with one or more substituents independently selected from: (a), (b), and (c):
[0131] (a) Halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN;
[0132] (b)C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 、-NO2、
[0133] -CN、C 3-6 Carbocyclic and 5- to 6-membered heterocyclic rings, each C 3-6 The carbocyclic and 5- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 11 ,
[0134] -N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and
[0135] (c)C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0136] In some embodiments, for compounds or salts of Formula (I) or (IA), A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrazole, imidazole, oxazole, isoxazole, oxadiazole, triazole and tetrazole, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 In some embodiments, A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 In some embodiments, A is selected from pyrazole, imidazole, oxazole, isoxazole, oxadiazole, triazole and tetrazole, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0137] In some embodiments, for compounds or salts of Formula (I) or (IA), A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrazole, imidazole, oxazole, isoxazole, oxadiazole, triazole and tetrazole, any of which is optionally substituted with one or more substituents independently selected from C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 、-NO2、-CN、C 3-6 Carbocyclic and 5- to 6-membered heterocyclic rings, each C 3-6The carbocyclic and 5- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 In some embodiments, A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl, any of which is optionally substituted with one or more substituents independently selected from C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 、-NO2、-CN、C 3-6 Carbocyclic and 5- to 6-membered heterocyclic rings, each C 3-6 The carbocyclic and 5- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 In some embodiments, A is selected from pyrazole, imidazole, oxazole, isoxazole, oxadiazole, triazole and tetrazole, any of which is optionally substituted with one or more substituents independently selected from C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 、-NO2、-CN、C 3-6 Carbocyclic and 5- to 6-membered heterocyclic rings, each C 3-6 The carbocyclic and 5- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0138] In some embodiments, for compounds or salts of Formula (I) or (IA), A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrazole, imidazole, oxazole, isoxazole, oxadiazole, triazole and tetrazole, any of which is optionally substituted with one or more substituents independently selected from C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 In some embodiments, A is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl, any of which is optionally substituted with one or more substituents independently selected from C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 In some embodiments, A is selected from pyrazole, imidazole, oxazole, isoxazole, oxadiazole, triazole and tetrazole, any of which is optionally substituted with one or more substituents independently selected from C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0139] In some embodiments, for compounds or salts of Formula (I) or (IA), A is a saturated C 3-6 Carbocyclic ring, the saturated C 3-6 The carbocyclic ring is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, A is C 3-6 Cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, A is a saturated C3-6 A carbocyclic ring selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, A is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, A is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 11 , C 1-3 Alkyl and C 1-3 In some embodiments, A is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, any of which is optionally substituted with one or more substituents independently selected from fluorine, chlorine, bromine, C 1-3 Alkyl and C 1-3 In some embodiments, A is selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, any of which is optionally substituted with one or more substituents independently selected from fluorine, chlorine, and bromine.
[0140] In some embodiments, for compounds or salts of Formula (I) or (IA), A is an optionally substituted C 3-6 In some embodiments, A is selected from C 3-5 Carbon ring, C 3-4 Carbon ring, C 4-6 Carbon ring and C 5-6 In some embodiments, A is selected from C3 carbocycle, C4 carbocycle, C5 carbocycle and C6 carbocycle, any of which is optionally substituted. In some embodiments, A is an optionally substituted C 3-6 saturated carbocyclic or optionally substituted unsaturated C 3-6 In some embodiments, A is C 3-6 A is a carbocyclic ring selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl, any of which is optionally substituted. 3-6 A saturated carbocyclic ring selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, any of which is optionally substituted.
[0141] In some embodiments, for compounds or salts of Formula (I) or (IA), A is a saturated C 3-6 carbocyclic ring, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, A is a saturated C 3-6 A carbocyclic ring selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, A is a saturated C 3-6 A carbocyclic ring selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, any of which is optionally substituted with one or more substituents independently selected from fluorine, chlorine, bromine, -OR 11 、-N(R 11 )2.-CN, C 1-3 Alkyl and C 1-3 In some embodiments, A is a saturated C 3-6 A carbocyclic ring selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, any of which is optionally substituted with one or more substituents independently selected from fluorine, chlorine, bromine, -OR 11 , C 1-3 Alkyl and C 1-3 In some embodiments, A is cyclopropyl, which is optionally substituted with halogen, C 1-3 Alkyl and C 1-3 In some embodiments, A is cyclopropyl, which is optionally substituted with fluorine, chlorine, bromine, C 1-3 Alkyl and C 1-3 In some embodiments, A is cyclopropyl, which is optionally substituted with fluorine, chlorine and bromine. In some embodiments, A is
[0142] In some embodiments, for compounds or salts of formula (I) or (IA), A is a 5- to 6-membered heterocyclic ring comprising at least one heteroatom selected from nitrogen, oxygen, sulfur, and combinations thereof. In some embodiments, A is a 5- to 6-membered heterocyclic ring comprising at least one heteroatom selected from nitrogen, oxygen, and combinations thereof. In some embodiments, A is a 5- to 6-membered heterocyclic ring comprising at least one heteroatom selected from nitrogen, sulfur, and combinations thereof. In some embodiments, A is a 5- to 6-membered heterocyclic ring comprising at least one heteroatom selected from oxygen, sulfur, and combinations thereof. In some embodiments, A is a 5- to 6-membered heterocyclic ring comprising at least one heteroatom selected from oxygen, sulfur, and combinations thereof. In some embodiments, A is a 5- to 6-membered heterocyclic ring comprising at least one nitrogen heteroatom. In some embodiments, A is a 5- to 6-membered heterocyclic ring comprising at least one oxygen heteroatom. In some embodiments, A is a 5- to 6-membered heterocyclic ring comprising at least one sulfur heteroatom. In some embodiments, A is a 5- to 6-membered saturated heterocyclic ring. In some embodiments, A is a 5- to 6-membered unsaturated heterocyclic ring. In some embodiments, A is a 5- to 6-membered heteroaryl.
[0143] In some embodiments, for compounds or salts of formula (I) or (IA), A is a 5 to 6-membered heteroaryl group comprising at least one heteroatom selected from nitrogen, oxygen, sulfur, and combinations thereof. In some embodiments, A is a 5 to 6-membered heteroaryl group comprising at least one heteroatom selected from nitrogen, oxygen, and combinations thereof. In some embodiments, A is a 5 to 6-membered heteroaryl group comprising at least one heteroatom selected from nitrogen, sulfur, and combinations thereof. In some embodiments, A is a 5 to 6-membered heteroaryl group comprising at least one heteroatom selected from oxygen, sulfur, and combinations thereof. In some embodiments, A is a 5 to 6-membered heteroaryl group comprising at least one heteroatom selected from oxygen, sulfur, and combinations thereof. In some embodiments, A is a 5 to 6-membered heteroaryl group comprising at least one nitrogen heteroatom. In some embodiments, A is a 5 to 6-membered heteroaryl group comprising at least one oxygen heteroatom. In some embodiments, A is a 5 to 6-membered heteroaryl group comprising at least one sulfur heteroatom.
[0144] In some embodiments, for the compound or salt of Formula (I) or (IA), A is a 5- to 6-membered heteroaryl group optionally substituted with one or more substituents independently selected from:
[0145] C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2, -CN; and 5 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11, -NO2 and -CN; and
[0146] C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0147] In some embodiments, for compounds or salts of Formula (I) or (IA), A is pyrazole, imidazole, triazole, tetrazole, thiophene, oxazole, isoxazole, thiazole, isothiazole, oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine and triazine, any of which is optionally substituted with one or more substituents independently selected from:
[0148] C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2, -CN; and 5 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and
[0149] C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0150] In some embodiments, for the compound or salt of Formula (I) or (IA), A is a 6-membered heteroaryl optionally substituted with one or more substituents independently selected from:
[0151] C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R11 、C(O)OR 11 , -NO2, -CN; and 5 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and
[0152] C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0153] In some embodiments, for compounds or salts of Formula (I) or (IA), A is pyridine, pyridazine, pyrimidine, pyrazine, and triazine, any of which is optionally substituted with one or more substituents independently selected from:
[0154] C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2, -CN; and 5 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and
[0155] C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0156] In some embodiments, for the compound or salt of Formula (I) or (IA), A is a 5-membered heteroaryl optionally substituted with one or more substituents independently selected from:
[0157] C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2, -CN; and 5 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and
[0158] C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0159] In some embodiments, for compounds or salts of Formula (I) or (IA), A is pyrazole, imidazole, oxazole, isoxazole, oxadiazole, triazole, tetrazole, any of which is optionally substituted with one or more substituents independently selected from:
[0160] C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2, -CN; and 5 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and
[0161] C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11, -NO2 and -CN.
[0162] In some embodiments, for the compound or salt of Formula (I) or (IA), A is pyrazole and oxadiazole, each of which is optionally substituted with one or more substituents independently selected from:
[0163] C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2, -CN; and 5 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and
[0164] C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
[0165] In some embodiments, for the compound or salt of Formula (I) or (IA), A is selected from pyrazole and oxadiazole, each of which is optionally substituted with one or more substituents independently selected from C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkyl-OR 11 and C substituted by a 5- to 6-membered saturated heterocyclic ring 1-3 alkyl.
[0166] In some embodiments, for the compound or salt of Formula (I) or (IA), A is selected from pyrazole and oxadiazole, each of which is optionally substituted with methyl, ethyl, propyl, and isopropyl.
[0167] In some embodiments, for the compound or salt of Formula (I) or (IA), A is selected from: In some embodiments, A is selected from In some embodiments, A is In some embodiments, A is In some embodiments, A is In some embodiments, A is selected from In some embodiments, A is In some embodiments, A is
[0168] In some embodiments, for compounds or salts of Formula (I) or (IA), A is selected from pyrazole and oxadiazole, each of which is optionally substituted by C 1-3 Haloalkyl and C 1-3 Alkyl-OR 11 In some embodiments, A is selected from: In some embodiments, A is selected from In some embodiments, A is In some embodiments, A is In some embodiments, A is In some embodiments, A is
[0169] In some embodiments, for compounds or salts of Formula (I) or (IA), A is selected from pyrazole and oxadiazole, each of which is optionally substituted by C 1-3 Alkyl substituted, the C 1-3 The alkyl group is substituted with a 5- to 6-membered saturated heterocyclic ring. In some embodiments, A is selected from pyrazole and oxadiazole, each of which is optionally substituted with C 1-3 Alkyl substituted, the C 1-3 The alkyl group is substituted with pyrrolidine, pyrazolidine, imidazolidine, tetrahydrofuran, tetrahydrothiophene, oxathiolane, piperidine, piperazine, tetrahydropyran, thiazane, dithiane, morpholine, and thiomorpholine.
[0170]
[0171] In some embodiments, for the compound or salt of Formula (I) or (IA), A is selected from pyrazole and oxadiazole, each of which is optionally substituted with one or more substituents independently selected from saturated C 3-6 Carbocyclic ring, the saturated C 3-6 The carbocyclic ring is optionally substituted with one or more substituents selected from the group consisting of: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN. In some embodiments, A is selected from pyrazole and oxadiazole, each of which is optionally substituted with a cyclopropyl group, wherein the cyclopropyl group is optionally substituted with one or more fluorine or chlorine atoms. In some embodiments, A is selected from: In some embodiments, A is In some embodiments, A is
[0172] In some embodiments, for the compound or salt of Formula (I) or (IA), R 2 Selected from -N(R C )C(O)N(R D )(R E In some embodiments, R 2 Selected from -N(R C )C(O)N(R D )(R E ),in:
[0173] R C Selected from hydrogen;
[0174] R D Selected from C 1-6 Alkyl and saturated C 3-6 carbocyclic ring, any of which is optionally substituted by one or more substituents independently selected from: -OR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 , -NO2 and -CN; and
[0175] R E Selected from C 1-6 Alkyl and saturated C 3-6 carbocyclic ring, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 19 、-N(R 19 )2. -C(O)R 19 、-C(O)OR 19 , -NO2 and -CN.
[0176] In some embodiments, for the compound or salt of Formula (I) or (IA), R 2 Selected from -N(R C )C(O)N(R D )(R E In some embodiments, R 2 Selected from -N(R C )C(O)N(R D )(R E ),in:
[0177] R C Selected from hydrogen;
[0178] RD Selected from C 1-6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, any of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 , -NO2 and -CN; and
[0179] R E Selected from C 1-6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, any of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 19 、-N(R 19 )2. -C(O)R 19 、-C(O)OR 19 , -NO2 and -CN.
[0180] In some embodiments, for the compound or salt of Formula (I) or (IA), R D Selected from C 1-3 Alkyl and cyclopropyl, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and R E Selected from C 1-3 In some embodiments, R E Selected from C 1-3 Alkyl and cyclopropyl, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 19 、-N(R 19 )2, -NO2 and -CN; and R D Selected from C 1-3 In some embodiments, R 2 Selected from: In some embodiments, R 2 yes In some embodiments, R 2 yes
[0181] In some embodiments, for the compound or salt of Formula (I) or (IA), R 2 Selected from -N(R A )C(O)(R B ); and R A Selected from C 1-6 Alkyl, the C1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 15 、-N(R 15 )2. -C(O)R 15 、-C(O)OR 15 , -NO2 and -CN. In some embodiments, R 2 Selected from -N(R A )C(O)(R B ); and R A Selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 15 and -N(R 15 )2. In some embodiments, R 2 Selected from -N(R A )C(O)(R B ); and R A Selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from -C(O)R 15 、-C(O)OR 15 , NO2 and -CN. In some embodiments, R 2 Selected from -N(R A )C(O)(R B ); and R A It's hydrogen.
[0182] In some embodiments, for the compound or salt of Formula (I) or (IA), R 2 Selected from -N(R A )C(O)(R B ); and R B Selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 , -NO2 and -CN. In some embodiments, R 2 Selected from -N(R A )C(O)(R B ); and R B Selected from C 1-6Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of C 3-6 carbocyclic and 5- to 6-membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN. In some embodiments, R 2 Selected from -N(R A )C(O)(R B ); and R B Selected from C 3-6 A carbocyclic ring or a 4- to 6-membered heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN. In some embodiments, R 2 Selected from -N(R A )C(O)(R B ); and R B Selected from C 3-6 A carbocyclic ring or a 4- to 6-membered heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN.
[0183] In some embodiments, for the compound or salt of Formula (I) or (IA), R 2 Selected from -N(R A )C(O)(R B );R A is hydrogen; and R B Selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16)C(O)OR 16 , -NO2 and -CN. In some embodiments, R 2 Selected from -N(R A )C(O)(R B );R A is hydrogen; and R B Selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of C 3-6 carbocyclic and 5- to 6-membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN. In some embodiments, R 2 Selected from -N(R A )C(O)(R B );R A is hydrogen; and R B Selected from C 3-6 A carbocyclic ring or a 4- to 6-membered heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN. In some embodiments, R 2 Selected from -N(R A )C(O)(R B ); and R A is hydrogen; R B Selected from C 3-6 A carbocyclic ring or a 4- to 6-membered heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN.
[0184] In some embodiments, for the compound or salt of Formula (I) or (IA), R 2 Selected from -N(R A )C(O)(R B );R AIt is C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 , -NO2, -CN; and R B Selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 , -NO2 and -CN. In some embodiments, R 2 Selected from -N(R A )C(O)(R B );R A It is C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 , -NO2, -CN; and R B Selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of C 3-6 carbocyclic and 5- to 6-membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN. In some embodiments, R 2 Selected from -N(R A )C(O)(R B );R A It is C 1-6 Alkyl, the C 1-6The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 , -NO2, -CN; and R B Selected from C 3-6 A carbocyclic ring or a 4- to 6-membered heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN. In some embodiments, R 2 Selected from -N(R A )C(O)(R B ); and R A It is C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 、-NO2、-CN;R B Selected from C 3-6 A carbocyclic ring or a 4- to 6-membered heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN.
[0185] In some embodiments, for the compound or salt of Formula (I) or (IA), R 2 Yes-N(R A )C(O)(R B ),in:
[0186] R A Selected from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; and
[0187] R B Selected from:
[0188] C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 ,
[0189] -N(R 16 )C(O)OR 16 、-NO2、-CN;C 3-6 carbocyclic and 5- to 6-membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 16 ,
[0190] -N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN; and
[0191] 4 to 6 membered heterocyclic ring, the 4 to 6 membered heterocyclic ring is optionally substituted by one or more substituents independently selected from: halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 ,
[0192] -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 ,
[0193] -NO2 and -CN.
[0194] In some embodiments, for the compound or salt of Formula (I) or (IA), R 2 Yes-N(R A )C(O)(R B ),in:
[0195] R A Selected from hydrogen, C 1-6 Alkyl and C 1-6haloalkyl; and
[0196] R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 , -NO2 and -CN.
[0197] In some embodiments, for the compound or salt of Formula (I) or (IA), R 2 Yes-N(R A )C(O)(R B ),in:
[0198] R A Selected from hydrogen, C 1-6 Alkyl and C 1-6 haloalkyl; and
[0199] R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of C 3-6 carbocyclic and 5- to 6-membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN.
[0200] In some embodiments, for the compound or salt of Formula (I) or (IA), R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 、-NO2、-CN、C 3-6 Carbocyclic and 5- to 6-membered heterocyclic rings, each C 3-6The carbocyclic and 5- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN.
[0201] In some embodiments, for the compound or salt of Formula (I) or (IA), R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 , -NO2 and -CN. In some embodiments, R A is hydrogen; and R B is selected from: methyl, ethyl, propyl and isobutyl, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 , -NO2 and -CN.
[0202] In some embodiments, for the compound or salt of Formula (I) or (IA), R B Selected from C 1-6 Alkyl and C 1-6 In some embodiments, R A is hydrogen; and R B Selected from C 1-6 Alkyl and C 1-6 In some embodiments, R A is hydrogen; and R B Selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from chlorine, fluorine and bromine. A is hydrogen; and R B Selected from C 1-6 Alkyl, the C 1-6The alkyl group is optionally substituted with one or more fluorine atoms. 2 Selected from: In some embodiments, R 2 Selected from: In some embodiments, R 2 Selected from:
[0203] In some embodiments, for the compound or salt of Formula (I) or (IA), R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 and N(R 16 )C(O)OR 16 In some embodiments, R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 and N(R 16 )C(O)OR 16 In some embodiments, R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from chlorine, fluorine, bromine, -OR 16 and -N(R 16 )C(O)OR 16 In some embodiments, R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of chlorine, fluorine, bromine and -N(R 16 )C(O)OR 16 In some embodiments, R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from -OR 16 and -N(R 16 )C(O)OR 16 In some embodiments, RA is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from chlorine, fluorine, bromine and -OR 16 .
[0204] In some embodiments, for the compound or salt of Formula (I) or (IA), R 2 Selected from:
[0205] In some embodiments, R 2 Selected from: In some embodiments, R 2 yes In some embodiments, R 2 yes
[0206] In some embodiments, for the compound or salt of Formula (I) or (IA), R B is optionally -OR 16 Substituted C 1-6 In some embodiments, R A is hydrogen; and R B is optionally -OR 16 Substituted C 1-6 In some embodiments, R A is hydrogen; and R B is optionally -OR 16 Substituted C 1-6 Alkyl, where R 16 Is -OC 1-6 Alkyl substituted C 1-6 In some embodiments, R 2 yes
[0207] In some embodiments, for the compound or salt of Formula (I) or (IA), R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of C 3-6 carbocyclic and 5 to 6 membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from the following halogen, -OR 16 、-N(R 16 )2, -NO2 and -CN. In some embodiments, R A is hydrogen; and RB Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of C 3-6 carbocyclic and 5- to 6-membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2, -NO2 and -CN.
[0208] In some embodiments, for the compound or salt of Formula (I) or (IA), R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of optionally substituted C 3-6 In some embodiments, R A is hydrogen; and R B Selected from: C 1-6 alkyl, optionally substituted with one or more substituents independently selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted with one or more cyclopropyl substituents. 2 Selected from: In some embodiments, R 2 yes In some embodiments, R 2 yes In some embodiments, R 2 yes
[0209] In some embodiments, for the compound or salt of Formula (I) or (IA), R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of 5-membered heterocyclic rings, the 5-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 16 、-N(R 16 )2, -NO2 and -CN. In some embodiments, R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of 5-membered heterocyclic rings, the 5-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 16 、-N(R 16 )2, -NO2 and -CN.
[0210] In some embodiments, for the compound or salt of Formula (I) or (IA), R A is hydrogen; and R B Selected from: C 1-6 alkyl, optionally substituted with one or more pyrazole, imidazole, triazole, tetrazole, thiophene, oxazole, isoxazole, thiazole, isothiazole, oxadiazole and thiadiazole, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2, -NO2 and -CN. In some embodiments, R A is hydrogen; and R B Selected from: C 1-6 alkyl, optionally substituted with one or more pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl and thiadiazolyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2, -NO2 and -CN. In some embodiments, R 2 yes
[0211] In some embodiments, for the compound or salt of Formula (I) or (IA), R B Selected from: optionally -N(R 16 )2 substituted C 1-6 alkyl; and R 16 At each occurrence, selected from hydrogen, C 1-3 alkyl and a 3- to 6-membered heterocyclic ring, wherein each C 1-3 Alkyl and 3 to 6 membered heterocyclic rings are optionally substituted. A is hydrogen; and R B Selected from: optionally -N(R 16 )2 substituted C 1-6 alkyl; and R 16 At each occurrence, selected from hydrogen, C 1-3 alkyl and a 3- to 6-membered heterocyclic ring, wherein each C 1-3 Alkyl and 3 to 6 membered heterocyclic rings are optionally substituted. 2 Selected from: In some embodiments, R 2 yes In some embodiments, R 2 yes In some embodiments, R 2 yes
[0212] In some embodiments, for the compound or salt of Formula (I) or (IA), R B is selected from a 4- to 6-membered heterocyclic ring, the 4- to 6-membered heterocyclic ring being optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN. In some embodiments, R B is selected from 4 to 6 membered saturated heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN. In some embodiments, R B Selected from azetidine and pyrrolidine, each of which is optionally substituted with halogen, -OR 13 、-C(O)R 16 、-C(O)OR 16 replace.
[0213] In some embodiments, for the compound or salt of Formula (I) or (IA), R A is hydrogen; and R Bis selected from a 4- to 6-membered heterocyclic ring, the 4- to 6-membered heterocyclic ring being optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN. In some embodiments, R A is hydrogen; and R B is selected from 4 to 6 membered saturated heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN. In some embodiments, R A is hydrogen; and R B Selected from azetidine and pyrrolidine, each of which is optionally substituted with halogen, -OR 13 、-C(O)R 16 、-C(O)OR 16 replace.
[0214] In some embodiments, for the compound or salt of Formula (I) or (IA), R 2 Selected from: In some embodiments, R 2 Selected from: In some embodiments, R 2 Selected from:
[0215] In some embodiments, for the compound or salt of Formula (I) or (IA), is selected from 4 to 6 membered monocyclic heterocycles and 5 to 10 membered bicyclic fused heterocycles, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 13 、-N(R 13 )2, -NO2, CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2, -NO2 and -CN.
[0216] In some embodiments, for the compound or salt of Formula (I) or (IA), is selected from 4 to 6 membered monocyclic heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2 and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen and -OR 13 In some embodiments, is selected from azetidine, pyrrolidine, pyrazolidine, imidazolidine, piperidine, morpholine and piperazine, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2 and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halogen and -OR 13 In some embodiments, selected from pyrrolidine, piperidine, morpholine and piperazine, each of which is optionally substituted by one or more selected from -OR 13 、-N(R 13 )2 and C 1-6 In some embodiments, Selected from: In some embodiments, yes In some embodiments, yes In some embodiments, yes
[0217] In some embodiments, for the compound or salt of Formula (I) or (IA), is selected from pyrrolidine, piperidine, morpholine and piperazine, each of which is optionally substituted with one or more selected from C1-3 The alkyl group is substituted with a substituent, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halogen and -OR 13 In some embodiments, is selected from pyrrolidine, piperidine, morpholine and piperazine, each of which is optionally substituted with one or more selected from C 1-3 The alkyl group is substituted with a substituent, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of chlorine, fluorine, bromine and -OR 13 In some embodiments, Selected from: In some embodiments, Selected from: In some embodiments, Selected from: In some embodiments, Selected from: In some embodiments, Selected from: In some embodiments, Selected from: In some embodiments, Selected from: In some embodiments, Selected from: In some embodiments, yes
[0218] In some embodiments, for the compound or salt of Formula (I) or (IA), is selected from a 7- to 10-membered bicyclic heterocycle, any of which is optionally substituted by one or more substituents independently selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with halogen, -OR 13 、-N(R 13 )2, -NO2 and -CN are substituted. In some embodiments, is selected from a 7- to 10-membered bicyclic heterocycle, any one of which is optionally replaced by C 1-3 In some embodiments, is selected from 7 to 10 membered bicyclic heterocyclic rings, any of which is optionally substituted with methyl, ethyl, propyl and isopropyl. Selected from: In some embodiments, Selected from: In some embodiments, Selected from:
[0219] In some embodiments, for the compound or salt of Formula (I) or (IA), is selected from a 5- to 8-membered spirocyclic heterocyclic ring, any of which is optionally substituted by one or more substituents independently selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with halogen, -OR 13 、-N(R 13 )2, -NO2 and -CN are substituted. In some embodiments, is selected from 5 to 8 membered spirocyclic heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from methyl, ethyl, propyl and isopropyl, any of which is optionally substituted by halogen, -OR 13 、-N(R 13 )2, -NO2 and -CN are substituted. In some embodiments, yes
[0220] In some embodiments, for the compound or salt of formula (I), formula (I) is represented by formula (IA): wherein each substituent is as defined in formula (I).
[0221] In some embodiments, Formula (I) or Formula (IA) is selected from:
[0222]
[0223]
[0224]
[0225]
[0226]
[0227]
[0228]
[0229]
[0230]
[0231]
[0232]
[0233]
[0234]
[0235]
[0236]
[0237]
[0238]
[0239]
[0240]
[0241]
[0242] In certain aspects, the present disclosure provides a compound or salt represented by the structure of formula (I), wherein: A is a 5-membered heteroaryl selected from pyrazole, imidazole, oxazole, isoxazole, oxadiazole, triazole and tetrazole,
[0243] Any of which is optionally substituted by one or more substituents independently selected from halogen,
[0244] -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 11 ,
[0245] -N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN, for example, A is pyrazole, the pyrazole
[0246] Optionally, one or more halogens, C 1-6 Alkyl or C 1-6 Haloalkyl substitution;
[0247] R 1 Selected from hydrogen, halogen, -OR 12 、-N(R 12 )2, -NO2, -CN, C 1-6 Alkyl and C 1-6 Haloalkyl, for example, R 1 It is C1-6 Alkyl or C 1-6 Haloalkyl;
[0248] R 2 Yes-N(R A )C(O)(R B );
[0249] R A Selected from hydrogen, C 1-6 Alkyl and C 1-6 Haloalkyl, for example, R A It is hydrogen;
[0250] R B Selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 , -NO2, - and CN, for example, R B It is C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more halogen, -OR 16 or-C(O)OR 16 replace;
[0251] is selected from pyrrolidine, piperidine, morpholine and piperazine, each of which is optionally substituted with one or more selected from C 1-3 The alkyl group is substituted with a substituent, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halogen and -OR 13 ,For example, is piperazine, the piperazine optionally being replaced by one or more C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkyl-OR 13 replace;
[0252] n is selected from 0, 1 and 2, for example, n is 1;
[0253] R 3 Selected from halogen, C 1-3 Alkyl and C 1-3 Haloalkyl, for example, R 3 is a halogen; and
[0254] R 11 , R12 , R 13 and R 16 Each occurrence is independently selected from hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN, such as R 11 , R 12 , R 13 and R 16 are independently hydrogen, C 1-3 Alkyl or C 1-3 Halogenated alkyl.
[0255] In certain aspects, the present disclosure provides compounds or salts represented by the structure of formula (I), wherein:
[0256] A is saturated C 3-6 A carbocyclic ring selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, any of which is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2.-CN, C 1-6 Alkyl and C 1-6 Haloalkyl, for example, A is cyclopropyl, the cyclopropyl group is optionally substituted with one or more halogen, C 1-6 Alkyl or C 1-6 Haloalkyl substitution;
[0257] R 1 Selected from hydrogen, halogen, -OR 12 、-N(R 12 )2, -NO2, -CN, C 1-6 Alkyl and C 1-6 Haloalkyl, for example, R 1 It is C 1-6 Alkyl or C 1-6 Haloalkyl;
[0258] R 2 Yes-N(R A )C(O)(R B );
[0259] R A Selected from hydrogen, C 1-6 Alkyl and C 1-6 Haloalkyl, for example, R A It is hydrogen;
[0260] R B Selected from C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 , -NO2, - and CN, for example, R B It is C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more halogen, -OR 16 or-C(O)OR 16 replace;
[0261] is selected from pyrrolidine, piperidine, morpholine and piperazine, each of which is optionally substituted with one or more selected from C 1-3 The alkyl group is substituted with a substituent, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halogen and -OR 13 ,For example, is piperazine, the piperazine optionally being replaced by one or more C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Alkyl-OR 13 replace;
[0262] n is selected from 0, 1 and 2, for example, n is 1;
[0263] R 3 Selected from halogen, C 1-3 Alkyl, C 1-3 Haloalkyl, for example, R 3 is a halogen; and
[0264] R 11 , R 12 , R 13 and R 16 Each occurrence is independently selected from hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OC1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN, such as R 11 , R 12 , R 13 and R 16 are independently hydrogen, C 1-3 Alkyl or C 1-3 Halogenated alkyl.
[0265] Chemical entities with carbon-carbon double bonds or carbon-nitrogen double bonds can exist in Z or E form (or cis or trans form). In addition, some chemical entities can exist in various tautomeric forms. Unless otherwise specified, specific compounds described herein are also intended to include all Z, E and tautomeric forms.
[0266] "Isomers" are different compounds with the same molecular formula. "Stereoisomers" are isomers that differ only in the way atoms are arranged in space. "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. When appropriate, the term "(±)" is used to specify a racemic mixture. "Diastereomers" or "diastereomers" are stereoisomers that have at least two asymmetric atoms but are not mirror images of each other. Absolute stereochemistry is specified according to the Cahn-Ingold-Prelog RS system. When a compound is a pure enantiomer, the stereochemistry at each chiral carbon can be specified with R or S. Resolved compounds with unknown absolute configuration can be specified as (+) or (-) according to the direction (right-handed or left-handed) in which they rotate plane polarized light at the wavelength of the sodium D line. Certain compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms, whose asymmetric centers may be defined as (R)- or (S)- in terms of absolute stereochemistry. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. The optical activity of the compounds may be analyzed by any suitable method, including, but not limited to, chiral chromatography and polarimetry, and the degree of dominance of one stereoisomer over another may be determined.
[0267] When stereochemistry is not specified in the chemical structure, the molecules with stereocenters described herein include isomers, such as enantiomers and diastereomers, enantiomeric mixtures (including racemates), diastereomeric mixtures and other mixtures, as long as they can be prepared by ordinary technicians in the field by routine experiments. In certain embodiments, a single enantiomer or diastereomer (i.e., optically active form) can be obtained by asymmetric synthesis or by the resolution of a racemate or a diastereomeric mixture. If possible, the resolution of a racemate or a diastereomeric mixture can be completed by conventional methods, such as crystallization or chromatography in the presence of a resolving agent, such as using a chiral high pressure liquid chromatography (HPLC) column. In addition, a mixture of two enantiomers enriched in one of the two enantiomers can be purified by recrystallization and / or wet grinding to provide a further optically enriched form of the main enantiomer.
[0268] In certain embodiments, the compositions of the present disclosure may include two or more enantiomers or diastereomers of the compound, wherein a single enantiomer or diastereomer accounts for at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 98% by weight, or at least about 99% by weight or more of the total weight of all stereoisomers. Methods for producing substantially pure enantiomers are well known to those skilled in the art. For example, a single stereoisomer substantially free of its stereoisomers, such as an enantiomer, can be obtained by resolving a racemic mixture using a method such as using an optically active resolving agent to form diastereomers (Stereochemistry of Carbon Compounds, (1962), EL Elliel, McGraw Hill; Lochmuller (1975) J. Chromatogr., 113 (3): 283-302). Racemic mixtures of chiral compounds can be separated and isolated by any suitable method, including but not limited to: (1) forming ionic diastereomeric salts with chiral compounds and separating by fractional crystallization or other methods, (2) forming diastereomeric compounds with chiral derivatizing agents, separating the diastereomers, and converting to pure stereoisomers, and (3) separating substantially pure or enriched stereoisomers directly under chiral conditions. Another method for separating enantiomers is to use a Diacel chiral column and eluting with an organic mobile phase, such as is performed by Chiral Technologies (www.chiraltech.com) on a fee-for-service basis.
[0269] "Tautomers" refers to molecules in which it is possible for a proton to move from one atom of a molecule to another atom of the same molecule. In certain embodiments, the compounds disclosed herein exist as tautomers. In cases in which tautomerism is possible, a chemical equilibrium of tautomers will exist. The exact ratio of tautomers depends on several factors, including physical state, temperature, solvent, and pH. Some examples of tautomeric equilibrium include:
[0270]
[0271] In some embodiments, the compounds disclosed herein can be used in different isotopically enriched forms, such as in 2 H. 3 H. 11 C. 13 C and / or 14 In one particular embodiment, the compound is deuterated in at least one position. Such deuterated forms can be prepared by the procedures described in U.S. Pat. Nos. 5,846,514 and 6,334,997. As described in U.S. Pat. Nos. 5,846,514 and 6,334,997, deuteration can improve metabolic stability and / or efficacy, thereby increasing the duration of action of the drug.
[0272] In certain embodiments, some or all of the compounds disclosed herein 1 H atoms are 2 H atom replacement. Methods for the synthesis of deuterium-containing compounds are known in the art and include, by way of non-limiting example only, the following synthetic methods.
[0273] Deuterium substituted compounds are synthesized using various methods such as those described in: Dean, Dennis C., ed., Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [Curr., Pharm. Des., 2000; 6(10)] 2000, p. 110; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.
[0274] Deuterated starting materials are readily available and are amenable to the synthetic methods described herein to provide the synthesis of deuterated compounds. A large number of deuterated reagents and building blocks are commercially available from chemical suppliers such as Aldrich Chemical Co.
[0275] The compounds of the present disclosure optionally contain unnatural ratios of atomic isotopes at one or more of the atoms that make up such compounds. For example, the compounds may be labeled with isotopes such as deuterium ( 2 H), tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C) Use 2 H. 11 C. 13 C. 14 C. 15 C. 12 N. 13 N. 15 N. 16 N. 16 O. 17 O. 14 F. 15 F. 16 F. 17 F. 18 F. 33 S. 34 S. 35 S.36 S. 35 Cl, 37 Cl, 79 Br, 81 Br and 125 All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.
[0276] The present disclosure includes salts of compounds of formula (I), particularly pharmaceutically acceptable salts. The compounds of the present disclosure may have sufficiently acidic functional groups, sufficiently basic functional groups, or both functional groups, and may react with any of a number of inorganic bases and inorganic and organic acids to form salts. Alternatively, inherently charged compounds, such as those with quaternary nitrogen, may form salts with appropriate counterions, such as halides such as bromides, chlorides, or fluorides.
[0277] Synthetic chemistry transformations and methods useful for synthesizing the compounds described herein are known in the art, and include, for example, those described in R. Larock, Comprehensive Organic Transformations (1989); T. W. Greene and PGM Wuts, Protective Groups in Organic Synthesis, 2nd ed. (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis (1995).
[0278] Pharmaceutical preparations
[0279] In some aspects, the present disclosure provides a pharmaceutical composition comprising a compound or salt of Formula (I) and at least one pharmaceutically acceptable excipient.
[0280] The pharmaceutical composition can be formulated using one or more physiologically acceptable carriers, including excipients and adjuvants. The formulation can be modified according to the selected route of administration. The pharmaceutical composition comprising the compound, salt or conjugate can be manufactured, for example, by lyophilizing the compound, salt or conjugate, mixing, dissolving, emulsifying, encapsulating or embedding the conjugate. The pharmaceutical composition may also include the compound, salt or conjugate in free base form or in the form of a pharmaceutically acceptable salt.
[0281] Any compound or salt of formula (I) can be formulated into any suitable pharmaceutical preparation. The pharmaceutical preparation of the present disclosure generally contains an active ingredient (e.g., any compound or salt of formula (I)) and one or more pharmaceutically acceptable excipients or carriers, including but not limited to: inert solid diluents and fillers, diluents, sterile aqueous solutions and various organic solvents, penetration enhancers, antioxidants, solubilizers and adjuvants.
[0282] Pharmaceutical compositions can also be prepared from any compound or salt of formula (I) and one or more pharmaceutically acceptable excipients suitable for transdermal, inhalation, sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural or intraspinal administration. The preparation of such pharmaceutical compositions is well known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, 10th ed., McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, 3rd ed., Churchill Livingston, New York, 1990; Katzung, ed., Basic and Clinical Pharmacology, 9th ed., McGraw Hill, 2003; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, 10th ed., McGraw Hill, 2001; Remingtons Pharmaceutical Sciences, 20th ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, 32nd ed. (The Pharmaceutical Press, London, 1999).
[0283] Treatment
[0284] In certain embodiments, the compound or salt of formula (I) or its salt can be used to treat or prevent diseases or conditions mediated directly or indirectly by IL-17A. Such diseases include inflammatory diseases and conditions, proliferative diseases (e.g., cancer), autoimmune diseases, and other diseases described herein. The method generally involves administering a therapeutically effective amount of a compound disclosed herein or a pharmaceutical composition thereof to an individual.
[0285] Increased levels of IL-17A have been associated with several conditions, including airway inflammation, rheumatoid arthritis (RA), osteoarthritis, bone erosion, intraperitoneal abscesses and adhesions, inflammatory bowel disease (IBD), allograft rejection, psoriasis, psoriatic arthritis, ankylosing spondylitis, certain types of cancer, angiogenesis, atherosclerosis, and multiple sclerosis (MS). Both IL-17A and IL-17R are upregulated in the synovial tissue of RA patients. IL-17A plays its role in the pathogenesis of RA through IL-1-β and TNF-α dependent and independent pathways. IL-17A stimulates the secretion of other cytokines and chemokines such as TNF-α, IL-1β, IL-6, IL-8, and Gro-α. IL-17A directly promotes the disease progression of RA. Injection of IL-17A into the knee of mice promotes joint destruction independent of IL-Iβ activity (Ann Rheum Dis 2000, 59:529-32). Anti-IL-1β antibodies are ineffective against IL-17A-induced inflammation and joint damage (J. Immunol 2001, 167:1004-1013). In a streptococcal cell wall (SCW)-induced murine arthritis model, IL-17A induces inflammatory cell infiltration and proteoglycan depletion in wild-type, IL-1β knockout and TNF-α knockout mice. IL-17A knockout mice are phenotypically normal in the absence of antigenic challenge, but have significantly reduced arthritis after type II collagen immunization (J. Immunol 2003, 171:6173-6177). Increased levels of IL-17A-secreting cells have also been observed in the facet joints of patients with ankylosing spondylitis (HAppel et al., Arthritis Res Therap. 2011, 13:R95).
[0286] In certain aspects, the disclosure provides methods of modulating IL-17A in an individual in need thereof, comprising administering to the individual a compound or salt of Formula (I). In certain embodiments, a compound or salt of Formula (I) inhibits IL-17A activity in an individual in need thereof.
[0287] In certain embodiments, the compounds or salts of formula (I) are used to treat or prevent inflammatory diseases or conditions. In certain embodiments, the compounds or salts of formula (I) are administered to a subject in need thereof to treat an inflammatory disease or condition, such as psoriasis.
[0288] In certain embodiments, the compounds or salts of formula (I) are used to treat or prevent an inflammatory disease or condition selected from the group consisting of plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, rheumatoid arthritis, palmoplantar psoriasis, spondyloarthritis, and non-infectious uveitis. In certain embodiments, the compounds or salts of formula (I) are used to treat or prevent psoriasis. Example
[0289] Having generally described the invention, it will be more readily understood by reference to the following examples, which are included merely for the purpose of illustrating certain aspects and embodiments of the invention and are not intended to limit the invention in any way.
[0290] The following synthetic schemes are provided for the purpose of illustration and not limitation. The following examples illustrate various methods for preparing the compounds described herein. It should be understood that those skilled in the art will be able to prepare these compounds by similar methods or by combining other methods known to those skilled in the art. It should also be understood that those skilled in the art will be able to prepare in a manner similar to that described below by using appropriate starting materials and modifying the synthetic routes as needed. In general, starting materials and reagents can be obtained from commercial suppliers, or synthesized according to sources known to those skilled in the art, or prepared as described herein.
[0291] Examples 1-8 show general methods for preparing the claimed IL-17A modulators. Examples 9-10 illustrate bioassays for IL-17A / A and IL-17A / F inhibition. Example 11 illustrates comparative data for selected claimed IL-17A modulators with reference compounds.
[0292] Table 1 shows spectroscopic data, bioassay inhibition, and synthetic methods for the claimed IL-17A modulators. Table 2 shows selected claimed IL-17A modulators and selected comparative compounds. Table 2.6 shows microsomal stability data for selected claimed IL-17A modulators and selected comparative compounds. Table 2.6 shows rat pharmacokinetic data for selected claimed IL-17A modulators and selected comparative compounds.
[0293] Example 1—Synthesis of Intermediates A and B
[0294]
[0295] Step 1: At 5°C under N2, n-BuLi (2.5M, 163.41mL, 1.5 equivalents) was added dropwise to a solution of (methoxymethyl)triphenylphosphine chloride (140.04g, 408.52mmol, 1.5 equivalents) in THF (1000mL). After the addition, the mixture was reacted at 5°C for 1 hour, and then dicyclopropyl ketone (30g, 272.35mmol, 30.71mL, 1 equivalent) was added dropwise. The resulting mixture was stirred at 60°C for 12 hours. H2O (200mL) was added to the reaction and extracted with ethyl acetate (500mL*2). The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate = 100:1 to 50:1). Compound 1 (30 g, 217.07 mmol, 79.70% yield) was obtained as a yellow oil. 1 H NMR: (400MHz, CDCl3) δ5.87(s,1H),3.58(s,3H),1.84-1.78(m,1H),0.85-0.73(m ,1H),0.73-0.72(m,2H),0.61-0.57(m,2H),0.47-0.45(m,2H),0.25-0.23(m,2H).
[0296] Step 2: To a mixture of compound 1 (30 g, 217.07 mmol, 1 eq.) in dioxane (500 mL) and H2O (50 mL) was added TsOH (149.52 g, 868.27 mmol, 4 eq.). The mixture was stirred at 110°C for 3 h. Saturated NaHCO3 (1000 mL) was added to the reaction and extracted with ethyl acetate (1000 mL*2). The combined organic layers were dried over Na2SO4, filtered and concentrated. The crude product was distilled in vacuum (120°C, 0.1 MPa pressure). Compound 2 (21 g, 169.11 mmol, 77.91% yield) was obtained as a colorless oil. 1 H NMR: (400MHz, CDCl3) δ9.76-9.72(m,1H),1.04-0.96(m,1H),0.87-0.85(m,2H),0.58-0.53(m,4H),0.26-0.24(m,4H).
[0297] Step 3: KCN (5.51 g, 84.55 mmol, 3.62 mL, 1.5 equiv) and (NH4)2CO3 (16.25 g, 169.11 mmol, 18.05 mL, 3 equiv) were added to a mixture of compound 2 (7 g, 56.37 mmol, 1 equiv) in MeOH (35 mL) and H2O (35 mL). The mixture was stirred at 60 ° C for 12 hours. Saturated NaHCO3 (200 mL) was added to the reaction and extracted with ethyl acetate (200 mL*2). The combined organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 10: 1 to 1: 1). Compound 3 (6 g, 30.89 mmol, 54.80% yield, 100% purity) was obtained as a white solid. LC-MS:rt=0.87min; m / z=195.1,[M+H] + . 1 H NMR: (400MHz, CDCl3) δ8.52(s,1H),6.51(s,1H),4.26(s,1H),0.87-0.79(m,3H ),0.75-0.72(m,1H),0.52-0.50(m,2H),0.50-0.49(m,2H),0.24-0.21(m,3H).
[0298] Step 4: NaOH (5M, 102.97mL, 10 equivalents) was added to a mixture of compound 3 (10 g, 51.49 mmol, 100% purity, 1 equivalent) in H2O (200 mL). The mixture was stirred at 100°C for 12 hours. The mixture was then cooled at 20°C, and the pH of the mixture was adjusted to 7-8 with 5M HCl (1 mL). Boc2O (16.85 g, 77.23 mmol, 17.74 mL, 1.5 equivalents) and THF (100 mL) were slowly added dropwise to the above mixture. The mixture was stirred at 25°C for 4 hours. H2O (100 mL) was added to the reaction and extracted with ethyl acetate (100 mL*2). The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 10: 1 to 1: 1). Compound 4 (11 g, 38.02 mmol, 73.85% yield, 93.1% purity) was obtained as a yellow oil. LC-MS: rt = 0.93 min; m / z = 292.0, [M+Na] + . 1H NMR: (400MHz, CDCl3) δ10.03(s,1H),6.04-5.27(m,1H),4.56-4.37(m,1H),1.45(s,9H),0.78-0.52(m,3H),0.27-0.25(m,4H),0.23-0.20(m,4H).
[0299] Step 5: A mixture of compound 4 (2.0 g, 6.92 mmol, 93.1% purity, 1 eq.), 4-methoxybenzyl alcohol (1.15 g, 8.30 mmol, 1.03 mL, 1.2 eq.), DCC (2.14 g, 10.38 mmol, 2.10 mL, 1.5 eq.) and DMAP (845.49 mg, 6.92 mmol, 1 eq.) in DCM (50 mL) was stirred at 20 °C for 16 h. H2O (100 mL) was added to the reaction and extracted with DCM (100 mL*2). The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna C18 (250*70 mm, 10 um); mobile phase: [water (0.1% TFA)-ACN]; B%: 58%-86%, 21 min). Compound 5 (2 g, 5.07 mmol, 73.31% yield, 98.8% purity) was obtained as a white solid. LC-MS: rt = 1.10 min; m / z = 412.2, [M+Na] + . 1 H NMR: (400MHz, CDCl3) δ7.30-7.27(m,2H),6.90-6.87(m,2H),5.26(d,J=9.2Hz,1H),5.09(s,2H),4.55-4.36(m,1H),3. 82(s,3H),1.45(s,9H),0.73-0.63(m,3H),0.48-0.47(m,3H),0.19-0.18(m,1H),0.17-0.15(m,3H),0.14-0.01(m,1H).
[0300] Step 6: The residue of compound 5 was purified by Prep-SFC (column: DAICEL CHIRALPAK AY-H (250 mm*30 mm, 10 um); mobile phase: [0.1% NH3H2O ETOH]; B%: 70%-70%, 10.5; 160 min). Compound 6 (0.9 g, 2.30 mmol, 45.36% yield, 99.6% purity) was obtained as a yellow oil. LC-MS: rt = 1.09 min; m / z = 412.2, [M+Na] + .1 H NMR: (400 MHz, CDCl3) δ 7.30-7.27 (m, 2H), 6.90-6.87 (m, 2H), 5.26 (d, J = 8.8 Hz, 1H), 5.09 (s, 2H), 4.55-4.36 (m, 1H), 3.81 (s, 3H), 1.45 (s, 9H), 0.73-0.63 (m, 3H), 0.48-0.47 (m, 3H), 0.19-0.18 (m, 1H), 0.17-0.15 (m, 3H), 0.14-0.01 (m, 1H). 7 (0.9 g, 2.30 mmol, 45.36% yield, 99.7% purity) was obtained as a yellow oil. LC-MS: rt=1.09min; m / z=412.2, [M+Na] + . 1 H NMR: (400MHz, CDCl3) δ7.30-7.27(m,2H),6.90-6.87(m,2H),5.26(d,J=9.2Hz,1H),5.09(s,2H),4.55-4.36(m,1H),3. 82(s,3H),1.45(s,9H),0.73-0.63(m,3H),0.48-0.47(m,3H),0.19-0.18(m,1H),0.17-0.15(m,3H),0.14-0.01(m,1H).
[0301] Step 7a: Pd / C (100 mg, 10.0% purity) was added to a solution of compound 6 (250 mg, 641 umol, 1.00 equiv) in DCM (2.00 mL) under N2. The suspension was degassed in vacuo and purged with H2 several times. The mixture was stirred at 25 °C under H2 (15 Psi) for 24 hours. The reaction mixture was filtered and the filtrate was concentrated. Intermediate A (0.170 g, 631 umol, 98.3% yield) was obtained as a colorless oil. LC-MS: rt = 0.85 min; m / z = 292.2, [M+Na] + .
[0302] X-ray crystallographic analysis of intermediate A confirmed the following absolute stereochemistry:
[0303]
[0304] Step 7b: Under N2, Pd / C (100 mg, 10.0% purity) was added to a solution of compound 7 (250 mg, 641 umol, 1.00 equivalent) in DCM (2.00 mL). The suspension was degassed in vacuum and purged with H2 several times. The mixture was stirred at 25 ° C under H2 (15 Psi) for 24 hours. The reaction mixture was filtered and the filtrate was concentrated. Intermediate B (0.170 g, 631 umol, 98.3% yield) was obtained as a colorless oil, which was used without further characterization.
[0305] Example 2. General Scheme - Synthesis of Intermediate C
[0306]
[0307] Step 1: To a solution of compound 8 (25.0 g, 73.0 mmol, 1.00 equiv) in DCM (200 mL) was added HCl / dioxane (4 M, 182 mL, 10.0 equiv) at 0°C. The mixture was stirred at 25°C for 3 hours. The reaction mixture was concentrated to give the product. Compound 9 (17.0 g, 61.0 mmol, 83.5% yield, HCl) was obtained as a yellow solid. LC-MS: rt = 0.16 min; m / z = 243.2, [M+H] + The synthesis method of compound 8 can be found in US application number 17 / 118,947 and US application number 16 / 783,268.
[0308] Step 2: At 0°C, a solution of compound 9 (17.0 g, 61.0 mmol, 1.00 eq, HCl) in dioxane (170 mL) was added with a solution of Na2CO3 (19.4 g, 183 mmol, 3.00 equiv) in H2O (170 mL) and Cbz-OSu (30.4 g, 122 mmol, 2.00 equiv). The mixture was stirred at 25°C for 12 hours. At 0°C, 100 mL of 1M HCl aqueous solution was added to quench the reaction mixture until pH = 4, and then extracted with ethyl acetate 400 mL (200 mL * 2). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. Compound 10 (22.0 g, 58.4 mmol, 95.8% yield) was obtained as a yellow oil. LC-MS: rt = 0.84 min; m / z = 375.1, [MH] - .
[0309] Step 3: At 0°C, TMSCHN2 (2M, 43.8mL, 1.50 equivalents) was added to a solution of compound 10 (22.0g, 58.4mmol, 1.00 equivalents) in MeOH (22.0mL) and DCM (220mL), and the mixture was stirred at 25°C for 12 hours. At 0°C, 50.0mL 10% AcOH was added to quench the reaction mixture, which was then diluted with 200mL H2O and extracted with DCM 400mL (200mL*2). The combined organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to obtain a residue. The residue was purified by column chromatography (SiO2, petroleum ether: ethyl acetate = 100: 1 to 10: 1). Compound 11 (21.0g, 53.8mmol, 92.0% yield) was obtained as a yellow oil. LC-MS: rt=0.92min; m / z=413.1, [M+Na] + .
[0310] Step 4: To a solution of compound 11 (21.0 g, 53.8 mmol, 1.00 equiv) in EtOH (300 mL) was added NH4Cl (14.3 g, 268 mmol, 5.00 equiv) in H2O solution (100 mL), Fe (15.0 g, 268 mmol, 5.00 equiv). The mixture was stirred at 80 ° C for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to remove EtOH, then diluted with H2O (100 mL), and extracted with DCM (200 mL*2). The combined organic layer was washed with brine (200 mL*2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. Compound 12 (19.0 g, 52.7 mmol, 98.0% yield) was obtained as a white solid. LC-MS: rt=0.96 min; m / z=361.3, [M+H] + .
[0311] Step 5: To a solution of compound 12 (2.50 g, 6.94 mmol, 1.00 equiv) and intermediate A (2.39 g, 8.88 mmol, 1.28 equiv) in pyridine (20.0 mL) was added EDCI (3.99 g, 20.8 mmol, 3.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (50.0 mL) and extracted with DCM (50.0 mL*3). The combined organic layer was washed with Na2SO4 (50.0 mL*3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with MTBE (50.0 mL) at 25 ° C for 2 hours. The residue was purified by prep-HPLC (basic conditions, column: Waters Xbridge 150*25mm*5um; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 53%-83%, 10 min). Compound 13 (4.20 g, 6.87 mmol, 98.9% yield) was obtained as a white solid. LC-MS: rt=1.14 min; m / z=512.4, [M+H-boc] + .
[0312] Step 6: To a solution of compound 13 (3.00 g, 4.90 mmol, 1.00 equiv) in DCM (20.0 mL) was added HCl / dioxane (4 M, 12.2 mL, 10.0 equiv) at 0°C. The mixture was stirred at 25°C for 1 hour. The reaction mixture was concentrated under reduced pressure to give a residue. Compound 14 (2.60 g, 4.74 mmol, 96.7% yield, HCl) was obtained as a white solid. LC-MS: rt = 1.09 min; m / z = 512.4, [M+H] + .
[0313] Step 7: Compound 14 (2.10 g, 3.83 mmol, 1.00 eq, HCl) and 1-ethyl-1H-pyrazole-5-carboxylic acid ("A-COOH", ) (805 mg, 5.75 mmol, 1.50 equiv) was added to a solution of EDCI (2.20 g, 11.5 mmol, 3.00 equiv) in pyridine (5.00 mL). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with DCM (30.0 mL*3). The combined organic layers were washed with saturated aqueous NaHCO3 (30.0 mL*3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with MTBE (50.0 mL) at 25 ° C for 2 hours. Compound 15 (2.00 g, 3.16 mmol, 82.3% yield) was obtained as a white solid. LC-MS: rt=0.96 min; m / z=634.4, [M+H] + .
[0314] Step 8: To a solution of compound 15 (2.00 g, 3.16 mmol, 1.00 equiv) in MeOH (10.0 mL) and THF (10.0 mL) was added a solution of NaOH (378 mg, 9.47 mmol, 3.00 equiv) in H2O (2.00 mL) at 0°C. The mixture was stirred at 30°C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and 1 M HCl was added to adjust the pH to 2. The mixture was extracted with (50.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. Compound 16 (1.90 g, 3.07 mmol, 97.1% yield) was obtained as a white solid. LC-MS: rt=0.96 min; m / z=620.3, [M+H] + .
[0315] Step 9: To a solution of compound 16 (80.0 mg, 129 umol, 1.00 equiv) and (2S, 6R)-1,2,6-trimethylpiperazine ("HB") (24.8 mg, 193 umol, 1.50 equiv), DIEA (83.4 mg, 645.4 umol, 112.3 uL, 5.00 equiv) in DCM (5.00 mL) was added T3P (246 mg, 387 umol, 230 uL, 50% purity, 3.00 equiv) at 0°C. The mixture was stirred at 25°C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with DCM (30.0 mL*3). The combined organic layers were washed with saturated aqueous NaHCO3 (30.0 mL*2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by SFC (EW27685-21-P1A_c10) (column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 um); mobile phase: [0.1% NH3H2O IPA]; B%: 35%-35%, 3; 40 min, Rt = 1.929). Compound 17 (50.0 mg, 68.5 umol, 53.0% yield) was obtained as a white solid. LC-MS: rt = 1.06 min; m / z = 730.6, [M+H] + .
[0316] Step 10: Under N2 atmosphere, Pd / C (5.00 mg, 10% purity) was added to a solution of compound 17 (50.0 mg, 68.5 umol, 1.00 equiv.) in DCM (5.00 mL). The suspension was degassed and purged with H2 3 times. The mixture was stirred at 25 °C under H2 for 2 hours. The reaction mixture was filtered, and the filter cake was washed with 100 mL MeOH and then concentrated under reduced pressure to give a residue. Intermediate C (40.0 mg, 67.1 umol, 98.0% yield) was obtained as a white solid. LC-MS: rt = 0.91 min; m / z = 596.5, [M+H] + .
[0317] As described in Example 2, (A-COOH), expressed as:
[0318] In some embodiments, A in formula (I) or (IA) is represented by A and is an optionally substituted C 3-6In some embodiments, A in A-COOH is an optionally substituted C 3-6 carbocyclic or optionally substituted 5- to 6-membered heterocyclic ring.
[0319] As described in Example 2, HB is represented by:
[0320] Or a stereoisomer thereof. In some embodiments, as described in Example 2, HB is represented by:
[0321] In some embodiments, B in HB is represented by and is an optionally substituted 4- to 12-membered heterocyclic ring as described herein.
[0322] Example 3. Exemplary Schemes - Synthesis of Selected Compounds
[0323]
[0324] Example 3.1.1—Synthesis of Compound 223
[0325]
[0326] To a solution of intermediate C (40.0 mg, 67.0 umol, 1.00 equiv) and TEA (20.3 mg, 201 umol, 28.0 uL, 3.00 equiv) in DCM (5.00 mL) was added propionic anhydride (17.4 mg, 134 umol, 17.3 uL, 2.00 equiv) at 0 ° C. The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with DCM (30.0 mL*3). The combined organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 223 (35.2 mg, 51.4 umol, 76.6% yield, 95.3% purity) was obtained as a white solid. LC-MS:rt=0.95min; m / z=652.6,[M+H] + .
[0327] Compounds 202, 203, 204, 205, 208, 209, 212, 213, 214, 216, 217, 231, 232, 235, 236, 237, 238, 239, 240, 241, 242, 245, 250, 251, 252, 253, 257, 258, 264, 265, 266, 267, 268, 288 and 304 were all similarly synthesized using similar reaction conditions and appropriate anhydride reagents.
[0328] Example 3.1.2—Synthesis of Compound 204
[0329] To a solution of the appropriately substituted intermediate C (50.0 mg, 87.7 umol, 1.00 equiv) and TEA (26.6 mg, 263 umol, 36.6 uL, 3.00 equiv) in DCM (3.00 mL) was added propionic anhydride (13.7 mg, 105 umol, 13.5 uL, 1.20 equiv) at 0°C. The mixture was stirred at 25°C for 1 hour. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 204 (34.6 mg, 53.5 umol, 60.9% yield, 96.7% purity) was obtained as a white solid. LC-MS: rt = 0.84 min; m / z = 626.2, [M+H] + .
[0330] Example 3.1.3—Synthesis of Compound 205
[0331] To a solution of appropriately substituted intermediate C (40.0 mg, 66.9 umol, 1.00 equiv) and TEA (20.3 mg, 200 umol, 27.9 uL, 3.00 equiv) in DCM (5.00 mL) was added propionic anhydride (13.0 mg, 100 umol, 12.9 uL, 1.50 equiv) at 25°C. The mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 205 (41.8 mg, 63.3 umol, 94.6% yield, 99.1% purity) was obtained as a white solid. LC-MS: rt = 0.84 min; m / z = 654.3, [M+H] + .
[0332] Example 3.1.4—Synthesis of Compound 208
[0333] To a solution of appropriately substituted intermediate C (30.0 mg, 51.5 umol, 1.00 equiv) and TEA (26.0 mg, 257 umol, 35.8 uL, 5.00 equiv) in DCM (2.0 mL) was added propionic anhydride (10.0 mg, 77.3 umol, 9.97 uL, 1.50 equiv) at 0°C. The mixture was stirred at 25°C for 2 hours. The reaction was diluted with H2O (20.0 mL) and extracted with DCM (20.0 mL*3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 208 (34.0 mg, 50.0 umol, 93.8% yield, 99.6% purity) was obtained as a white solid. LC-MS:rt=0.73min; m / z=638.4,[M+H] + .
[0334] Example 3.1.5—Synthesis of Compound 209
[0335] To a solution of appropriately substituted intermediate C (50.0 mg, 85.9 umol, 1.00 equiv) and TEA (26 mg, 257 umol, 35.8 uL, 3.00 equiv) in DCM (5.00 mL) was added propionic anhydride (22.3 mg, 171 umol, 22.1 uL, 2.00 equiv) at 0°C. The mixture was stirred at 25°C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with DCM (30.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3um; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 23%-53%, 7min). Compound 209 (20.6 mg, 31.6 umol, 36.8% yield, 97.9% purity) was obtained as a white solid. LC-MS: rt=0.95 min; m / z=638.6, [M+H] + .
[0336] Example 3.1.16—Synthesis of Compound 212
[0337] To a solution of appropriately substituted intermediate C (40.0 mg, 67.0 umol, 1.00 equiv) and TEA (20.3 mg, 201 umol, 28.0 uL, 3.00 equiv) in DCM (5.00 mL) was added propionic anhydride (11.3 mg, 87.2 umol, 11.2 uL, 1.30 equiv). The mixture was stirred at 25 ° C for hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with DCM (30.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 212 (21.8 mg, 32.8 umol, 48.9% yield, 98.1% purity) was obtained as a white solid. LC-MS:rt=0.81min; m / z=652.2,[M+H] + .
[0338] Example 3.1.17—Synthesis of Compound 213
[0339] To a solution of appropriately substituted intermediate C (35.0 mg, 60.2 umol, 1.00 equiv) and TEA (18.3 mg, 181 umol, 25.1 uL, 3.00 equiv) in DCM (2.00 mL) was added propionic anhydride (8.61 mg, 66.2 umol, 8.52 uL, 1.10 equiv) at 0°C. The mixture was stirred at 15°C for 1 hour. The reaction mixture was diluted with H2O (10.0 mL) and extracted with DCM (10.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 213 (28.0 mg, 41.8 umol, 69.4% yield, 95.1% purity) was obtained as a white solid. LC-MS:rt=0.84min; m / z=638.4,[M+H] + .
[0340] Example 3.1.8—Synthesis of Compound 214
[0341] To a solution of appropriately substituted intermediate C (120 mg, 205 umol, 1.00 equiv) and TEA (62.4 mg, 616 umol, 85.8 uL, 3.00 equiv) in DCM (5.00 mL) was added acetic anhydride (41.9 mg, 411 umol, 38.5 uL, 2.00 equiv) at 0°C. The mixture was stirred at 25°C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with DCM (30.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 214 (37.1 mg, 57.7 umol, 28.1% yield, 97.4% purity) was obtained as a white solid. LC-MS:rt=0.88min; m / z=626.1,[M+H] + .
[0342] Example 3.1.9—Synthesis of Compound 216
[0343] To a solution of appropriately substituted intermediate C (50.0 mg, 85.3 umol, 1.00 equiv) and TEA (25.9 mg, 256 umol, 35.6 uL, 3.00 equiv) in DCM (5.0 mL) was added propionic anhydride (14.4 mg, 111 umol, 14.3 uL, 1.30 equiv) at 25°C. The mixture was stirred at 25°C for 1 hour. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 216 (54.0 mg, 80.6 umol, 94.5% yield, 95.8% purity) was obtained as a white solid. LC-MS: rt = 0.73 min; m / z = 642.5, [M+H] + .
[0344] Example 3.1.10—Synthesis of Compound 217
[0345] To a solution of appropriately substituted intermediate C (65.0 mg, 108 umol, 1.00 equiv) and TEA (32.9 mg, 325 umol, 45.2 uL, 3.00 equiv) in DCM (5.0 mL) was added propionic anhydride (21.1 mg, 162 umol, 20.9 uL, 1.50 equiv) at 25 °C. The mixture was stirred at 25 °C for 1 hour. The reaction mixture was diluted with H2O (40.0 mL) and extracted with DCM (40.0 mL*3). The combined organic layers were washed with brine (40.0 mL*3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 217 (69.6 mg, 103 umol, 95.4% yield, 97.5% purity) was obtained as a white solid. LC-MS:rt=0.73min; m / z=656.5,[M+H] + .
[0346] Example 3.1.11—Synthesis of Compound 232
[0347] To a solution of appropriately substituted intermediate C (60.0 mg, 99.3 umol, 1.00 equiv) and TEA (30.1 mg, 298 umol, 41.5 uL, 3.00 equiv) in DCM (5.0 mL) was added propionic anhydride (15.5 mg, 119 umol, 15.3 uL, 1.20 equiv). The mixture was stirred at 25 ° C for 1 hour. The reaction mixture was diluted with H2O (40.0 mL) and extracted with DCM (40.0 mL*3). The combined organic layer was washed with brine (40.0 mL*3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 232 (49.4 mg, 72.5 umol, 73.0% yield, 96.8% purity) was obtained as a white solid. LC-MS:rt=0.81min; m / z=674.2,[M+H] + .
[0348] Example 3.1.12—Synthesis of Compound 239
[0349] To a solution of appropriately substituted intermediate C (89.0 mg, 149 umol, 1.00 equiv) and TEA (45.5 mg, 449 umol, 62.5 uL, 3.00 equiv) in DCM (5.0 mL) was added propionic anhydride (39.0 mg, 299 umol, 38.6 uL, 2.00 equiv) at 0°C. The mixture was stirred at 25°C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with DCM (30.0 mL*3). The combined organic layers were washed with saturated aqueous NaHCO3 (30.0 mL*2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 239 (43.5 mg, 66.4 umol, 44.2% yield, 99.0% purity) was obtained as a white solid. LC-MS: rt = 0.84 min; m / z = 650.3, [M+H] + .
[0350] Example 3.1.13—Synthesis of Compound 245
[0351] To a solution of appropriately substituted intermediate C (80.0 mg, 146 umol, 1.00 equiv) and TEA (14.8 mg, 146 umol, 20.4 uL, 1.00 equiv) in DCM (5.00 mL) was added propionic anhydride (28.6 mg, 219 umol, 28.3 uL, 1.50 equiv) at 15 °C. The mixture was stirred at 15 °C for 12 hours. The reaction mixture was diluted with H2O (10.0 mL) and extracted with DCM (20.0 mL*2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 245 (49.3 mg, 76.6 umol, 52.2% yield, 93.5% purity) was obtained as a white solid. LC-MS:rt=0.74min; m / z=602.4,[M+H] + .
[0352] Example 3.1.14—Synthesis of Compound 250
[0353] To a solution of the appropriately substituted intermediate C (50.0 mg, 87.7 umol, 1.00 equiv) and TEA (26.6 mg, 263 umol, 36.6 uL, 3.00 equiv) in DCM (3.00 mL) was added propionic anhydride (13.7 mg, 105 umol, 13.5 uL, 1.20 equiv) at 0°C. The mixture was stirred at 25°C for 1 hour. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 250 (34.6 mg, 53.5 umol, 60.9% yield, 96.7% purity) was obtained as a white solid. LC-MS: rt = 0.84 min; m / z = 626.2, [M+H] + .
[0354] Example 3.1.15—Synthesis of Compound 257
[0355] To a solution of the appropriately substituted intermediate C (100.0 mg, 172 umol, 1.00 equiv) and TEA (34.7 mg, 343 umol, 47.8 uL, 2.00 equiv) in DCM (1.0 mL) was added propionic anhydride (33.5 mg, 257 umol, 33.2 uL, 1.50 equiv). The mixture was stirred at 20 ° C for 2 hours. The reaction mixture was diluted with saturated aqueous NaHCO3 (3.0 mL) and water (3.0 mL), extracted with DCM (3.0 mL*3), and the combined organic layers were washed with brine (5.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, EtOAc: MeOH = 10: 1). Compound 257 (38.4 mg, 58.7 umol, 34.1% yield, 97.6% purity) was obtained as a white solid. LC-MS: rt = 0.74 min; m / z = 638.4, [M+H] + .
[0356] Example 3.1.16—Synthesis of Compound 258
[0357] To a solution of appropriately substituted intermediate C (100.0 mg, 168 umol, 1.00 equiv) and TEA (33.9 mg, 335 umol, 46.7 uL, 2.00 equiv) in DCM (1.0 mL) was added propionic anhydride (32.7 mg, 252 umol, 32.4 uL, 1.50 equiv) at 20°C. The mixture was stirred at 20°C for 2 hours. The reaction mixture was diluted with saturated aqueous NaHCO (3.0 mL) and water (3.0 mL), extracted with DCM (3.0 mL*3), and the combined organic layers were washed with brine (5.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25mm*10um; mobile phase: [water (0.225% FA)-ACN]; B%: 13%-43%, 10min) to obtain the desired product. Compound 258 (60.2mg, 91.5umol, 54.5% yield, 99.1% purity) was obtained as a white solid. LC-MS: rt=0.74min; m / z=652.5, [M+H] + .
[0358] Example 3.1.17—Synthesis of Compound 264
[0359] To a solution of appropriately substituted intermediate C (100.0 mg, 164 umol, 1.00 equiv) and TEA (33.3 mg, 329 umol, 45.8 uL, 2.00 equiv) in DCM (1.0 mL) was added propionic anhydride (32.1 mg, 247 umol, 31.8 uL, 1.50 equiv) at 20°C. The mixture was stirred at 20°C for 2 hours. The reaction mixture was diluted with saturated aqueous NaHCO3 (3.0 mL) and water (3.0 mL), extracted with DCM (3.0 mL*3), and the combined organic layers were washed with brine (5.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25mm*10um; mobile phase: [water (0.225% FA)-ACN]; B%: 14%-44%, 10min) to obtain the desired product. Compound 264 (75.1mg, 111umol, 67.7% yield, 98.5% purity) was obtained as a white solid. LC-MS: rt=0.75min; m / z=664.4, [M+H] + .
[0360] Example 3.1.18—Synthesis of Compound 265
[0361] To a solution of the appropriately substituted intermediate C (100.0 mg, 168 umol, 1.00 equiv) and TEA (33.9 mg, 336 umol, 46.7 uL, 2.00 equiv) in DCM (1.0 mL) was added propionic anhydride (32.7 mg, 252 umol, 32.4 uL, 1.50 equiv). The mixture was stirred at 20 ° C for 2 hours. The reaction mixture was diluted with saturated aqueous NaHCO3 (3.0 mL) and water (3.0 mL), extracted with DCM (3.0 mL*3), and the combined organic layers were washed with brine (5.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, EtOAc: MeOH = 10: 1). Compound 265 (32.0 mg, 47.6 umol, 28.3% yield, 97.0% purity) was obtained as a white solid. LC-MS: rt = 0.74 min; m / z = 652.5, [M+H] + .
[0362] Example 3.1.19—Synthesis of Compound 288
[0363] To a solution of the appropriately substituted intermediate C (130.0 mg, 232 umol, 1.00 equiv) and TEA (47.0 mg, 464 umol, 64.6 uL, 2.00 equiv) in DCM (2.0 mL) was added propionic anhydride (45.3 mg, 348 umol, 44.8 uL, 1.50 equiv) at 20°C. The mixture was stirred at 20°C for 2 hours. The reaction mixture was diluted with saturated aqueous NaHCO3 (3.0 mL) and water (3.0 mL), extracted with DCM (3.0 mL*3), and the combined organic layers were washed with brine (5.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, Plate 1, EtOAc:MeOH=5:1, R f =0.5). The residue was purified by Prep-HPLC (column: Phenomenex Synergi C18 150*25mm*10um; mobile phase: [water (0.225% FA)-ACN]; B%: 13%-43%, 10min) to obtain the desired product. Compound 288 (57.4mg, 92.6umol, 39.8% yield, 99.3% purity) was obtained as a white solid. LC-MS: rt=0.73min; m / z=616.4, [M+H] + .
[0364] Example 3.2.1—Synthesis of Compound 224
[0365]
[0366] To a solution of intermediate C (80.0 mg, 140 umol, 1.00 equiv) and N-cyclopropyl-N-methylcarbamoyl chloride (37.5 mg, 280 umol, 2.00 equiv) in DCM (3.00 mL) was added DMAP (85.7 mg, 702 umol, 5.00 equiv). The mixture was stirred at 25 ° C for 8 hours. The reaction mixture was diluted with H2O (40.0 mL) and extracted with DCM (40.0 mL*3). The combined organic layer was washed with brine (40.0 mL*3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, Ethyl acetate: Methanol = 5: 1). Compound 224 (37.0 mg, 54.1 umol, 38.5% yield, 97.5% purity) was obtained as a white solid. LC-MS:rt=0.79min; m / z=667.4,[M+H] + .
[0367] Compounds 225, 270, 271, 291, 295, 313 and 316 were also synthesized using similar reaction conditions and appropriate carbamoyl chloride reagents.
[0368] Example 3.2.2—Synthesis of Compound 225
[0369] To a solution of the appropriately substituted intermediate C (200 mg, 352 umol, 1.00 equiv) and N-cyclopropyl-N-methylcarbamoyl chloride (470 mg, 3,520 umol, 10.00 equiv) in DCM (5.00 mL) was added DMAP (150 mg, 1,230 umol, 3.50 equiv). The mixture was stirred at 20 ° C for 52 hours. The reaction mixture was diluted with H2O (20 mL) and extracted with DCM (20 mL*3). The combined organic layers were washed with brine (40.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: Methanol = 10: 1). Compound 225 (120 mg, 177 umol, 50.4% yield, 98.3% purity) was obtained as a white solid. LC-MS:rt=0.90min; m / z=665.1,[M+H] + .
[0370] Example 3.3.1—Synthesis of Compound 206
[0371]
[0372] To a solution of intermediate C (50.0 mg, 87.7 umol, 1.00 equiv) and methoxyacetic acid (10.2 mg, 114 umol, 8.71 uL, 1.30 equiv) in pyridine (3.00 mL) was added EDCI (50.4 mg, 263 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 3 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25mm*5um; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 35%-62%, 9min). Compound 206 (30.8 mg, 46.9 umol, 53.5% yield, 97.6% purity) was obtained as a white solid. LC-MS:rt=0.83min; m / z=642.2,[M+H] + .
[0373] Compounds 207, 210, 211, 215, 218, 219, 220, 221, 222, 226, 227, 228, 254, 255, 256, 259, 260, 261, 262, 263, 269, 272-287, 289, 290, 292-294, 298-303, 307-312, 314, 315, 317-342, 345-349, 361, 362, 343 and 344 were similarly synthesized using similar reaction conditions and appropriate carboxylic acid reagents.
[0374] Example 3.3.2—Synthesis of Compound 207
[0375] To a solution of appropriately substituted intermediate C (50.0 mg, 85.9 umol, 1.00 equiv) and methoxyacetic acid (11.6 mg, 128 umol, 9.84 uL, 1.50 equiv) in pyridine (5.00 mL) was added EDCI (49.4 mg, 257 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 207 (49.3 mg, 71.2 umol, 82.9% yield, 94.4% purity) was obtained as a white solid. LC-MS:rt=0.94min; m / z=654.6,[M+H] + .
[0376] Example 3.3.3—Synthesis of Compound 210
[0377] To a solution of the appropriately substituted intermediate C (50.0 mg, 85.9 umol, 1.00 equiv) and N-(ethoxycarbonyl)-N-methyl-L-alanine (18.0 mg, 103 umol, 1.20 equiv) in pyridine (5.0 mL) was added EDCI (49.4 mg, 257 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). The residue was then purified by prep-HPLC (basic conditions, column: Phenomenex Gemini-NX C18 75*30mm*3um; mobile phase: [water (0.225% FA)-ACN]; B%: 20%-50%, 7min). Compound 210 (13.2 mg, 17.0 umol, 19.8% yield, 94.8% purity) was obtained as a white solid. LC-MS: rt=0.99 min; m / z=739.6, [M+H] + .
[0378] Example 3.3.4—Synthesis of Compound 211
[0379] To a solution of appropriately substituted intermediate C (60.0 mg, 105 umol, 1.00 equiv) and N-(ethoxycarbonyl)-N-methyl-L-alanine (24.1 mg, 137 umol, 1.30 equiv) in pyridine (2.0 mL) was added EDCI (40.5 mg, 211 umol, 2.00 equiv). The mixture was stirred at 20 ° C for 1 hour. The reaction mixture was diluted with DCM (30.0 mL), washed with water (20.0 mL) and brine (20.0 mL), dried over Na2SO4 and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 211 (42.0 mg, 57.9 umol, 54.8% yield, 91.7% purity) was obtained as a white solid. LC-MS:rt=0.97min; m / z=725.6,[M+H] + .
[0380] Example 3.3.5—Synthesis of Compound 215
[0381] To a solution of appropriately substituted intermediate C (60.0 mg, 106 umol, 1.00 equiv) and methoxyacetic acid (14.3 mg, 159 umol, 12.1 uL, 1.50 equiv) in pyridine (1.00 mL) was added EDCI (60.8 mg, 318 umol, 3.00 equiv). The mixture was stirred at 15 ° C for 3 hours. The reaction mixture was diluted with H2O (15 mL) and extracted with ethyl acetate (20 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 215 (43.7 mg, 67.9 umol, 64.2% yield, 99.4% purity) was obtained as a white solid. LC-MS:rt=0.74min; m / z=640.4,[M+H] + .
[0382] Example 3.3.6—Synthesis of Compound 219
[0383] To a solution of the appropriately substituted intermediate C (45.0 mg, 77.3 umol, 1.00 equiv) and the sodium salt of 2-fluoropropionic acid (10.6 mg, 92.8 umol, 1.20 equiv) in DMF (5.0 mL) was added HOBT (20.9 mg, 154 umol, 2.00 equiv) and DIEA (20.0 mg, 154 umol, 26.9 uL, 2.00 equiv) and EDCI (29.6 mg, 154 umol, 2.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were washed with saturated NaHCO3 (30.0 mL*2) aqueous solution, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1) to obtain compound 219 (39.0 mg, 57.2 umol, 74.0% yield, 96.1% purity) as a white solid. LC-MS: rt=0.96 min; m / z=656.5, [M+H] + .
[0384] Example 3.3.7—Synthesis of Compound 220
[0385] To a solution of appropriately substituted intermediate C (50.0 mg, 87.7 umol, 1.00 equiv) and (S)-2-methoxypropionic acid (11.8 mg, 114 umol, 1.30 equiv) in pyridine (4.0 mL) was added EDCI (50.4 mg, 263 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 3 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25mm*5um; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 37%-64%, 9min). Compound 220 (33.6 mg, 51.1 umol, 58.3% yield, 99.8% purity) was obtained as a white solid. LC-MS:rt=0.85min; m / z=656.3,[M+H] + .
[0386] Example 3.3.8—Synthesis of Compound 221
[0387] To a solution of appropriately substituted intermediate C (50.0 mg, 85.9 umol, 1.00 equiv) and (S)-2-methoxypropionic acid (13.4 mg, 128 umol, 1.50 equiv) in pyridine (5.00 mL) was added EDCI (49.4 mg, 257 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 221 (37.7 mg, 54.1 umol, 62.9% yield, 95.7% purity) was obtained as a white solid. LC-MS:rt=0.94min; m / z=668.5,[M+H] + .
[0388] Example 3.3.9—Synthesis of Compound 222
[0389] To a solution of appropriately substituted intermediate C (60.0 mg, 106 umol, 1.00 equiv) and (S)-2-methoxypropionic acid (22.0 mg, 211 umol, 2.00 equiv) in pyridine (2.00 mL) was added EDCI (60.8 mg, 317 umol, 3.00 equiv). The mixture was stirred at 15 ° C for 3 hours. The reaction mixture was diluted with H2O (15 mL) and extracted with ethyl acetate (20 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 222 (40.4 mg, 60.8 umol, 57.5% yield, 98.4% purity) was obtained as a white solid. LC-MS:rt=0.75min; m / z=654.4,[M+H] + .
[0390] Example 3.3.10—Synthesis of Compound 226
[0391] To a solution of appropriately substituted intermediate C (50.0 mg, 85.9 umol, 1.00 equiv) and 2-cyclopropylacetic acid (12.9 mg, 128 umol, 1.50 equiv) in pyridine (5.0 mL) was added EDCI (49.4 mg, 257 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 226 (45.4 mg, 66.8 umol, 77.7% yield, 97.7% purity) was obtained as a white solid. LC-MS:rt=0.97min; m / z=664.6,[M+H] + .
[0392] Example 3.3.11—Synthesis of Compound 227
[0393] To a solution of appropriately substituted intermediate C (60.0 mg, 85.9 umol, 1.00 equiv) and 2-cyclopropylacetic acid (13.7 mg, 137 umol, 1.30 equiv) in pyridine (2.0 mL) was added EDCI (40.5 mg, 211 umol, 2.00 equiv). The mixture was stirred at 20 ° C for 1 hour. The reaction mixture was diluted with DCM (30.0 mL), washed with water (20.0 mL) and brine (20.0 mL), dried over Na2SO4 and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 227 (60.0 mg, 92.3 umol, 87.3% yield, 96.6% purity) was obtained as a white solid. LC-MS: rt = 0.95 min; m / z = 650.6, [M + H] + .
[0394] Example 3.3.12—Synthesis of Compound 228
[0395] To a solution of the appropriately substituted intermediate C (70.0 mg, 120 umol, 1.00 equiv) and the sodium salt of 2-fluoroacetic acid (19.1 mg, 180 umol, 1.50 equiv) in DMF (5.0 mL) was added HOBT (32.5 mg, 240 umol, 2.00 equiv) and DIEA (31.1 mg, 240 umol, 41.9 uL, 2.00 equiv) and EDCI (46.1 mg, 240 umol, 2.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were washed with saturated NaHCO3 (30.0 mL*2) aqueous solution, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA conditions, column: Phenomenex Gemini-NX C18 75*30mm*3um; mobile phase: [water (0.225% FA)-ACN]; B%: 15%-45%, 7min). Compound 228 (26.7mg, 39.3umol, 32.7% yield, 94.4% purity) was obtained as a white solid. LC-MS: rt=0.94min; m / z=642.5, [M+H] + .
[0396] Example 3.3.13—Synthesis of Compound 260
[0397] To a solution of appropriately substituted intermediate C (100.0 mg, 168 umol, 1.00 equiv) and (S)-2-methoxypropionic acid (20.9 mg, 201 umol, 1.20 equiv) in pyridine (1.0 mL) was added EDCI (64.3 mg, 335 umol, 2.00 equiv). The mixture was stirred at 20°C for 2 hours. The reaction mixture was diluted with saturated aqueous NaHCO3 (3.0 mL) and H2O (3.0 mL) and extracted with DCM (3.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25 mm*10 um; mobile phase: [water (0.225% FA)-ACN]; B%: 14%-44%, 10 min) to give the desired product. Compound 260 (61.8 mg, 88.9 umol, 52.9% yield, 98.2% purity) was obtained as a white solid. LC-MS: rt = 0.74 min; m / z = 682.6, [M+H] + .
[0398] Example 3.3.14—Synthesis of Compound 261
[0399] To a solution of the appropriately substituted intermediate C (100.0 mg, 164 umol, 1.00 equiv) and (S)-2-methoxypropionic acid (20.5 mg, 197 umol, 25.4 uL, 1.20 equiv) in pyridine (1.0 mL) was added EDCI (63.0 mg, 329 umol, 2.00 equiv). The mixture was stirred at 20 ° C for 2 hours. The reaction mixture was diluted with saturated aqueous NaHCO (3.0 mL) and water (3.0 mL), extracted with DCM (3.0 mL*3), and the combined organic layers were washed with brine (5.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25mm*10um; mobile phase: [water (0.225% FA)-ACN]; B%: 14%-44%, 10min) to obtain the desired product. Compound 261 (72.9mg, 104umol, 63.5% yield, 99.4% purity) was obtained as a white solid. LC-MS: rt=0.75min; m / z=694.4, [M+H] + .
[0400] Example 3.3.15—Synthesis of Compound 269
[0401] To a solution of the appropriately substituted intermediate C (70.0 mg, 131 umol, 1.00 equiv) and (ethoxycarbonyl)-L-proline (42.4 mg, 263 umol, 2.00 equiv) in pyridine (5.0 mL) was added EDCI (75.7 mg, 395 umol, 3.00 equiv). The mixture was stirred at 25 °C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were washed with saturated aqueous NaHCO3 (30 mL*2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 269 (34.5 mg, 50.8 umol, 38.6% yield, 99.2% purity) was obtained as a white solid. LC-MS:rt=0.83min; m / z=675.5,[M+H] + .
[0402] Example 3.3.16—Synthesis of Compound 272
[0403] To a solution of appropriately substituted intermediate C (50.0 mg, 94.0 umol, 1.00 equiv) and (S)-2-methoxypropionic acid (14.6 mg, 141 umol, 1.50 equiv) in pyridine (5.0 mL) was added EDCI (54.0 mg, 282 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with DCM (30.0 mL*3). The combined organic layers were washed with saturated NaHCO3 (30.0 mL*2) aqueous solution, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 272 (29.5 mg, 45.5 umol, 48.4% yield, 95.2% purity) was obtained as a white solid. LC-MS:rt=0.82min; m / z=618.2,[M+H] + .
[0404] Example 3.3.17—Synthesis of Compound 273
[0405] To a solution of appropriately substituted intermediate C (50.0 mg, 91.6 umol, 1.00 equiv) and (S)-2-methoxypropionic acid (14.3 mg, 137 umol, 1.50 equiv) in DCM (5.00 mL) was added EDCI (52.7 mg, 274 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 273 (32.5 mg, 48.8 umol, 53.3% yield, 94.7% purity) was obtained as a white solid. LC-MS:rt=0.83min; m / z=632.2,[M+H] + .
[0406] Example 3.3.18—Synthesis of Compound 274
[0407] To a solution of the appropriately substituted intermediate C (60.0 mg, 112 umol, 1.00 equiv) and (S)-1-(ethoxycarbonyl)azetidine-2-carboxylic acid (29.3 mg, 169 umol, 1.50 equiv) in pyridine (5.0 mL) was added EDCI (64.9 mg, 338 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were washed with saturated NaHCO3 (30.0 mL*2) aqueous solution, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 274 (32.8 mg, 46.7 umol, 41.4% yield, 97.9% purity) was obtained as a white solid. LC-MS: rt = 0.97 min; m / z = 687.5, [M+H] + .
[0408] Example 3.3.19—Synthesis of Compound 275
[0409] To a solution of the appropriately substituted intermediate C (190.0 mg, 348 umol, 1.00 equiv) and (S)-1-(ethoxycarbonyl)azetidine-2-carboxylic acid (90.4 mg, 522 mmol, 1.50 equiv) in pyridine (5.0 mL) was added EDCI (200 mg, 1.04 mmol, 3.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were washed with saturated NaHCO3 (30.0 mL*2) aqueous solution, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 275 (85.9 mg, 118 umol, 34.1% yield, 97.0% purity) was obtained as a white solid. LC-MS: rt = 0.82 min; m / z = 701.3, [M+H] + .
[0410] Example 3.3.20—Synthesis of Compound 276
[0411] To a solution of the appropriately substituted intermediate C (70.0 mg, 131 umol, 1.00 equiv) and (ethoxycarbonyl)-L-proline (49.2 mg, 263 umol, 2.00 equiv) in pyridine (5.0 mL) was added EDCI (75.7 mg, 395 umol, 3.00 equiv). The mixture was stirred at 25 °C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were washed with saturated aqueous NaHCO3 (30.0 mL*2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 276 (52.2 mg, 72.2 umol, 54.8% yield, 96.9% purity) was obtained as a white solid. LC-MS:rt=0.98min; m / z=701.5,[M+H] + .
[0412] Example 3.3.21—Synthesis of Compound 278
[0413] To a solution of appropriately substituted intermediate C (70.0 mg, 128 umol, 1.00 equiv) and (S)-1-(m-ethoxycarbonyl)azetidine-2-carboxylic acid (30.6 mg, 192 umol, 1.50 equiv) in pyridine (2.0 mL) was added EDCI (49.2 mg, 257 umol, 2.00 equiv). The mixture was stirred at 20 ° C for 2 hours. The reaction mixture was diluted with DCM (20.0 mL), and the organic phase was extracted with saturated NaHCO3 (10.0 mL) aqueous solution and DCM (10.0 mL * 2) and washed with water (20.0 mL) and brine (20.0 mL), then dried over Na2SO4 and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 278 (55.0 mg, 78.9 umol, 61.5% yield, 98.5% purity) was obtained as a white solid. LC-MS: rt = 0.73 min; m / z = 687.4, [M+H] + .
[0414] Example 3.3.22—Synthesis of Compound 279
[0415] To a solution of the appropriately substituted intermediate C (70.0 mg, 128 umol, 1.00 equiv) and (ethoxycarbonyl)-L-proline (48.0 mg, 256 umol, 2.00 equiv) in pyridine (5.0 mL) was added EDCI (73.7 mg, 384 umol, 3.00 equiv). The mixture was stirred at 25 °C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were washed with saturated aqueous NaHCO3 (30 mL*2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 279 (54.1 mg, 72.6 umol, 56.6% yield, 96.0% purity) was obtained as a white solid. LC-MS:rt=0.99min; m / z=715.5,[M+H] + .
[0416] Example 3.3.23—Synthesis of Compound 280
[0417] To a solution of the appropriately substituted intermediate C (70.0 mg, 132 umol, 1.00 equiv) and (m-ethoxycarbonyl)-L-proline (34.2 mg, 198 umol, 1.50 equiv) in pyridine (2.0 mL) was added EDCI (50.5 mg, 263 umol, 2.00 equiv). The mixture was stirred at 20 ° C for 12 hours. The reaction mixture was diluted with saturated aqueous NaHCO3 (10.0 mL) and extracted with DCM (10.0 mL*5), and the combined organic phases were washed with water (10.0 mL) and brine (10.0 mL), then dried over Na2SO4 and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 280 (60.0 mg, 87.4 umol, 66.4% yield, 98.3% purity) was obtained as a white solid. LC-MS:rt=0.74min; m / z=687.4,[M+H] + .
[0418] Example 3.3.24—Synthesis of Compound 281
[0419] To a solution of the appropriately substituted intermediate C (70.0 mg, 128 umol, 1.00 equiv) and (m-ethoxycarbonyl)-L-proline (33.3 mg, 192 umol, 1.50 equiv) in pyridine (2.0 mL) was added EDCI (49.2 mg, 257 umol, 2.00 equiv). The mixture was stirred at 20 ° C for 12 hours. The reaction mixture was diluted with saturated aqueous NaHCO3 (10.0 mL) and extracted with DCM (10.0 mL*5), and the combined organic phases were washed with water (10.0 mL) and brine (10.0 mL), then dried over Na2SO4 and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 281 (55.0 mg, 77.9 umol, 60.7% yield, 99.3% purity) was obtained as a white solid. LC-MS:rt=0.81min; m / z=701.2,[M+H] + .
[0420] Example 3.3.25—Synthesis of Compound 282
[0421] To a solution of the appropriately substituted intermediate C (70.0 mg, 128 umol, 1.00 equiv) and (ethoxycarbonyl)-L-alanine (41.3 mg, 256 umol, 2.00 equiv) in pyridine (5.0 mL) was added EDCI (73.7 mg, 384 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were washed with saturated NaHCO3 (30.0 mL*2) aqueous solution, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 282 (39.1 mg, 55.6 umol, 43.3% yield, 98.1% purity) was obtained as a white solid. LC-MS:rt=0.83min; m / z=689.5,[M+H] + .
[0422] Example 3.3.26—Synthesis of Compound 286
[0423] To a solution of appropriately substituted intermediate C (90.0 mg, 151 umol, 1.00 equiv) and 2-methoxyacetic acid (20.4 mg, 226 umol, 1.50 equiv) in pyridine (5.0 mL) was added EDCI (86.8 mg, 453 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were washed with saturated NaHCO3 (30.0 mL*2) aqueous solution, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 286 (100 mg, 148 umol, 98.0% yield, 97.9% purity) was obtained as a white solid. LC-MS:rt=0.82min; m / z=668.3,[M+H] + .
[0424] Example 3.3.27—Synthesis of Compound 287
[0425] To a solution of appropriately substituted intermediate C (90.0 mg, 151 umol, 1.00 equiv) and (S)-2-methoxypropionic acid (23.5 mg, 226 umol, 1.50 equiv) in pyridine (5.0 mL) was added EDCI (86.8 mg, 453 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with DCM (30.0 mL*3). The combined organic layers were washed with saturated NaHCO3 (30.0 mL*2) aqueous solution, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 287 (39.3 mg, 57.3 umol, 37.9% yield, 99.4% purity) was obtained as a white solid. LC-MS:rt=0.82min; m / z=682.3,[M+H] + .
[0426] Example 3.3.28—Synthesis of Compound 289
[0427] To a solution of appropriately substituted intermediate C (130.0 mg, 232 umol, 1.00 equiv) and methoxyacetic acid (25.1 mg, 278 umol, 21.2 uL, 1.20 equiv) in pyridine (5.0 mL) was added EDCI (89.0 mg, 464 umol, 2.00 equiv). The mixture was stirred at 20 ° C for 2 hours. The reaction mixture was diluted with saturated aqueous NaHCO3 (3.0 mL) and H2O (3.0 mL) and extracted with DCM (3.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, plate 1, EtOAc:MeOH=5:1, R f =0.5). The residue was then purified by prep-HPLC (column: Phenomenex Synergi C18 150*25mm*10um; mobile phase: [water (0.225% FA)-ACN]; B%: 14%-44%, 10min) to obtain the desired product. Compound 289 (27.7mg, 43.1umol, 18.6% yield, 98.4% purity) was obtained as a white solid. LC-MS: rt=0.73min; m / z=632.4, [M+H] + .
[0428] Example 3.3.29—Synthesis of Compound 290
[0429] To a solution of the appropriately substituted intermediate C (130.0 mg, 232 umol, 1.00 equiv) and (S)-2-methoxypropionic acid (29.0 mg, 279 umol, 1.20 equiv) in pyridine (2.0 mL) was added EDCI (89.0 mg, 464 umol, 2.00 equiv). The mixture was stirred at 20 °C for 2 hours. The reaction mixture was diluted with saturated aqueous NaHCO3 (3.0 mL) and H2O (3.0 mL) and extracted with DCM (3.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, plate 1, EtOAc:MeOH=5:1, R f =0.5). The residue was then purified by prep-HPLC (column: Phenomenex Synergi C18 150*25mm*10um; mobile phase: [water (0.225% FA)-ACN]; B%: 14%-44%, 10min) to obtain the desired product. Compound 290 (52.9mg, 81.1umol, 34.9% yield, 99.0% purity) was obtained as a white solid. LC-MS: rt=0.74min; m / z=646.4, [M+H] + .
[0430] Example 3.3.30—Synthesis of Compound 308
[0431] To a solution of appropriately substituted intermediate C (70.0 mg, 122 umol, 1.00 equiv) and (S)-2-methoxypropionic acid (25.5 mg, 245 umol, 2.00 equiv) in pyridine (5.0 mL) was added EDCI (70.6 mg, 368 umol, 3.00 equiv). The mixture was stirred at 25 ° C for 1 hour. The reaction mixture was diluted with H2O (40.0 mL) and extracted with DCM (40.0 mL*3). The combined organic layer was washed with brine (40.0 mL*3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 308 (63.5 mg, 93.5 umol, 76.0% yield, 96.5% purity) was obtained as a white solid. LC-MS:rt=0.76min; m / z=656.3,[M+H] + .
[0432] Example 3.3.31—Synthesis of Compound 319
[0433] To a solution of appropriately substituted intermediate C (70.0 mg, 120 umol, 1.00 equiv) and 2,2-dicyclopropylacetic acid (20.2 mg, 144 umol, 1.20 equiv) in pyridine (1.0 mL) was added EDCI (46.1 mg, 240 umol, 2.00 equiv). The mixture was stirred at 20 ° C for 2 hours. The reaction mixture was diluted with saturated aqueous NaHCO3 (3.0 mL) and water (3.0 mL), extracted with DCM (3.0 mL*3), and the combined organic layers were washed with brine (5 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, EtOAc: MeOH = 10: 1). Compound 319 (50.6 mg, 69.4 umol, 57.6% yield, 96.5% purity) was obtained as a white solid. LC-MS:rt=0.78min; m / z=704.4,[M+H] + .
[0434] Example 3.3.32—Synthesis of Compound 342
[0435] To a solution of the appropriately substituted intermediate C (120.0 mg, 202 umol, 1.00 equiv) and (S)-2-methoxypropionic acid (31.5 mg, 303 umol, 1.50 equiv) in pyridine (5.0 mL) was added EDCI (116 mg, 606 umol, 3.00 equiv). The mixture was stirred at 25 °C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were washed with saturated aqueous NaHCO3 (30.0 mL*2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 342 (84.7 mg, 119 umol, 59.0% yield, 95.7% purity) was obtained as a white solid. LC-MS:rt=0.82min; m / z=680.5,[M+H] + .
[0436] Example 3.3.33—Synthesis of Compound 347
[0437] To a solution of appropriately substituted intermediate C (100.0 mg, 179 umol, 1.00 equiv) and (S)-2-methoxypropionic acid (28.1 mg, 269 umol, 1.50 equiv) in pyridine (5.0 mL) was added EDCI (103 mg, 539 umol, 3.00 equiv). The mixture was stirred at 20 ° C for 3 hours. The reaction mixture was concentrated under reduced pressure to give a residue and diluted with DCM (30.0 mL), and the combined organic phase was washed with water (10.0 mL) and brine (10.0 mL), then dried over Na2SO4 and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 347 (34.4 mg, 52.9 umol, 29.4% yield, 98.6% purity) was obtained as a white solid. LC-MS:rt=0.98min; m / z=642.5,[M+H] + .
[0438] Example 3.3.34—Synthesis of Compound 348
[0439] To a solution of appropriately substituted intermediate C (80.0 mg, 140 umol, 1.00 equiv) and 2-methoxyacetic acid (18.9 mg, 210 umol, 16.0 uL, 1.50 equiv) in pyridine (5.0 mL) was added EDCI (80.7 mg, 421 umol, 3.00 equiv). The mixture was stirred at 20 ° C for 2 hours. The reaction mixture was concentrated under reduced pressure to give a residue and diluted with DCM (30.0 mL), and the combined organic phase was washed with water (10.0 mL) and brine (10.0 mL), then dried over Na2SO4 and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). Compound 348 (45.0 mg, 68.2 umol, 48.5% yield, 97.3% purity) was obtained as a white solid. LC-MS:rt=0.97min; m / z=642.5,[M+H] + .
[0440] Example 3.3.35—Synthesis of Compound 361
[0441] To a solution of appropriately substituted intermediate C (75.0 mg, 134 umol, 1.00 equiv) and (ethoxycarbonyl)-L-alanine (43.5 mg, 269 umol, 2.00 equiv) in pyridine (3.0 mL) was added EDCI (51.7 mg, 269 umol, 2.00 equiv). The mixture was stirred at 25°C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (neutral conditions; column: Waters Xbridge 150*25mm*5um; mobile phase: [water (10mMNH4HCO3)-ACN]; B%: 40%-70%, 10min). Compound 361 (17.6 mg, 23.1 umol, 17.1% yield, 92.1% purity) was obtained as a white solid. LC-MS: rt = 0.75 min; m / z = 699.4, [M+H] + .
[0442] Example 3.3.36—Synthesis of Compound 362
[0443] To a solution of appropriately substituted intermediate C (75.0 mg, 131 umol, 1.00 equiv) and (ethoxycarbonyl)-L-alanine (42.4 mg, 263 umol, 2.00 equiv) in pyridine (2.0 mL) was added EDCI (75.7 mg, 394 umol, 3.00 equiv). The mixture was stirred at 25° C. for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (neutral conditions; column: Waters Xbridge 150*25mm*5um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B%: 42%-72%, 10 min). Compound 362 (22.8 mg, 30.8 umol, 23.4% yield, 96.1% purity) was obtained as a white solid. LC-MS: rt = 0.85 min; m / z = 713.3, [M+H] + .
[0444] Example 3.4—Synthesis of Compound 360
[0445]
[0446] Step A: To a solution of intermediate C (70.0 mg, 122 umol, 1.00 equiv) and (2R)-2-{[(benzyloxy)carbonyl]amino}-3-fluoropropionic acid (59.2 mg, 245 umol, 2.00 equiv) in pyridine (2.00 mL) was added EDCI (70.6 mg, 368 umol, 3.00 equiv). The mixture was stirred at 25 °C for 2 hours. The reaction was diluted with H2O (20.0 mL), filtered and concentrated in vacuo. Compound 360, step A (90.0 g, 113 umol, 92.3% yield) was obtained as a yellow solid. LC-MS: rt = 0.87 min; m / z = 779.2, [M+H] + .
[0447]
[0448] Step B: Under N2, Pd / C (10.0 mg, 10% purity) was added to a solution of compound 360, step A (90.0 mg, 113 umol, 1.00 equiv.) in DCM (2.00 mL). The suspension was degassed in vacuum and purged with H2 several times. The mixture was stirred at 25 ° C under H2 (15 Psi) for 2 hours. The reactants were filtered and concentrated in vacuo. The residue was purified by prep-HPLC (neutral conditions; column: Waters Xbridge 150*25mm*5um; mobile phase: [water (NH4HCO3)-ACN]; B%: 36%-66%, min). Compound 360, step B (70.0 mg, 106 umol, 93.6% yield) was obtained as a white solid. LC-MS: rt=0.68 min; m / z=645.4, [M+H] + .
[0449]
[0450] Step C: At 0°C, TEA (32.9 mg, 325 umol, 45.3 uL, 3.00 equiv) and ethyl chloroformate (17.6 mg, 162 umol, 15.5 uL, 1.50 equiv) were added to a solution of compound 360, step B (70.0 mg, 108 umol, 1.00 equiv) in DCM (2.00 mL). The mixture was stirred at 0°C for 0.5 hours. LC-MS (EW24650-429-P1A1) showed that the desired mass was detected. The reaction was diluted with H2O (30.0 mL) and extracted with EtOAc (30.0 mL*3), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by Prep-TLC (SiO2, DCM: MeOH = 10: 1). 360 (30.6 mg, 41.9 umol, 38.6% yield, 98.0% purity) as a white solid. LC-MS: rt = 0.83 min; m / z = 717.4, [M+H] + .
[0451] Compounds 358, 359 and 363 were all synthesized using similar reaction conditions using appropriate carboxylic acids and haloformate reagents.
[0452] Example 3.5—Synthesis of Compound 306
[0453]
[0454] Step A: To a mixture of compound intermediate C (500 mg, 860 umol, 1.00 equiv) and (2S)-2-{[(tert-butoxy)carbonyl]amino}propionic acid (244 mg, 1.29 mmol, 1.50 equiv) in pyridine (4.00 mL) was added EDCI (330 mg, 1.72 mmol, 2.00 equiv) and stirred at 20 ° C for 3 hours. The reaction mixture was concentrated under reduced pressure to give a residue, which was then diluted with DCM (20.0 mL), and the combined organic phases were washed with water (10.0 mL) and brine (10.0 mL), then dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (plate 1, DCM:MeOH=10:1, R f =0.48) was purified. The desired product, compound 306, step A (458 mg, 608 umol, 70.8% yield, 100% purity) was obtained as a white solid. LC-MS: rt = 0.95 min; m / z = 753.3, [M+H] + .
[0455]
[0456] Step B: At 0°C, TFA (2.04 g, 17.9 mmol, 1.33 mL, 30.0 equiv) was added to a solution of compound 306, step A (450 mg, 598 umol, 1.00 equiv) in DCM (4.00 mL), then warmed to 20°C and stirred for 1 hour. The reaction mixture was concentrated under reduced pressure to give a residue, and the residue was diluted with saturated aqueous NaHCO3 (20.0 mL) solution, then extracted with DCM (10.0 mL*5), and the combined organic phases were washed with water (10.0 mL) and brine (10.0 mL), then dried over Na2SO4, filtered and concentrated under reduced pressure to give the desired product compound 306 residue, step B (340 mg, 521 umol, 87.1% yield) as a white solid. LC-MS: rt = 0.85 min; m / z = 653.3, [M+H] + .
[0457]
[0458] Step C: To a mixture of compound 306, step B (150 mg, 230 umol, 1.00 equiv) and 2-chloropyrimidine (52.6 mg, 460 umol, 2.00 equiv) in NMP (2.00 mL) was added DIEA (149 mg, 1.15 mmol, 200.uL, 5.00 equiv) and heated to 170 ° C. with microwave for 20 hours. The reaction mixture was diluted with water (20.0 mL) and extracted with DCM (10.0 mL*4), and the combined organic layers were washed with water (20.0 mL) and brine (20.0 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25mm*5um; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 32%-62%, min) to obtain the desired product compound 306 (80.0mg, 109umol, 47.6% yield) as a white solid. LC-MS: rt=0.95min; m / z=731.5, [M+H] + .
[0459] Compound 305 was synthesized using similar reaction conditions and appropriate reagents.
[0460] Example 3.6—Synthesis of Compound 296
[0461]
[0462] Step A: To a solution of intermediate C (150 mg, 257 umol, 1.00 equiv) and (2S)-2-{[(tert-butoxy)carbonyl]methyl)amino}propionic acid (78.6 mg, 386 umol, 1.50 equiv) in pyridine (5.00 mL) was added EDCI (148 mg, 773 umol, 3.00 equiv). The mixture was stirred at 15 ° C for 12 hours. H2O (10.0 mL) was added to the reaction mixture and extracted with DCM (20.0 mL*2). The combined organic layers were washed with saturated NaHCO3 (40 mL) aqueous solution, dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. Compound 296, step A (200 mg, crude) was obtained as a white solid. LC-MS: rt=0.78 min; m / z=767.5, [M+H] + .
[0463]
[0464] Step B: At 0°C, TFA (594 mg, 5.22 mmol, 386 uL, 20.0 equiv) was added to a solution of compound 296, step A (200 mg, 260 umol, 1.00 equiv) in DCM (5.00 mL). The mixture was stirred at 15°C for 2 hours. The reaction mixture was diluted with H2O (10.0 mL), and saturated aqueous NaHCO3 was added to adjust the pH to 9. The mixture was extracted with DCM (50.0 m*2). The combined organic layers were washed with saturated aqueous NaHCO3 (100 mL*4), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. Compound 296, step B (150 mg, 224 umol, 86.2% yield) was obtained as a yellow solid. LC-MS: rt = 0.92 min; m / z = 667.5, [M+H] + .
[0465]
[0466] Step C: 2-chloroethyl isocyanate (30.8 mg, 292 umol, 1.50 equiv) was added to a solution of compound 296, step B (130 mg, 194 umol, 1.00 equiv) and TEA (59.1 mg, 584 umol, 81.4 uL, 3.00 equiv) in DCM (2.00 mL). The mixture was stirred at 25 ° C for 12 hours. H2O (10.0 mL) was added to the reaction mixture and extracted with DCM (20.0 mL*2). The combined organic layer was washed with saturated NaHCO3 (40.0 mL) aqueous solution, dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain a residue. Compound 296, step C (120 mg, 155 umol, 79.7% yield) was obtained as a yellow oil. LC-MS:rt=0.95min; m / z=772.5,[M+H] + .
[0467]
[0468] Step D: To a solution of compound 296, step C (120 mg, 155 umol, 1.00 equiv.) in MeCN (10.0 mL) was added K2CO3 (64.4 mg, 466 umol, 3.00 equiv.). The mixture was stirred at 70°C for 12 hours. The reaction mixture was filtered and the filtrate was concentrated to give a crude product. The residue was purified by prep-HPLC (neutral conditions; column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B%: 26%-56%, 2 min). The residue was separated by SFC (conditions: column: DAICEL CHIRALCEL OD-H (250 mm*30 mm, 5 um); mobile phase: [0.1% NH3H2OETOH]; B%: 25%-25%, 5.0 min; 40 min min). Compound 296 (24.38 mg, 31.84 umol, 20.49% yield, 96.1% purity) was obtained as a white solid. LC-MS: rt = 0.95 min; m / z = 736.6, [M+H] + .
[0469] Example 4. Exemplary Schemes - Synthesis of Compounds 200, 229-230, 233-234, 243-244, 246-249 and 297
[0470]
[0471] Step 1: To a solution of compound 8 (5.00 g, 14.6 mmol, 1.00 equiv), (2R)-1,2-dimethylpiperazine (1.83 g, 16.0 mmol, 1.10 equiv) and DIEA (9.65 g, 74.6 mmol, 13.0 mL, 5.11 equiv) in DCM (50.0 mL) was added T3P (11.7 g, 18.5 mmol, 11.0 mL, 50% purity, 1.27 equiv) at -20°C, and the mixture was stirred for 12 hours. The reaction mixture was diluted with DCM (200 mL) and washed with saturated aqueous NaHCO3 (100 mL), H2O (100 mL) and brine (50.0 mL), the organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue to give the desired product compound 18, which was used without further purification or analysis.
[0472] Step 2: At 0 ° C, TFA (16.4 g, 143 mmol, 10.6 mL, 10.0 equivalents) was added to a solution of compound 18 (6.31 g, 14.3 mmol, 1.00 equivalent) in DCM (70.0 mL), and the mixture was then warmed to 20 ° and stirred for 12 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product compound 19 (6.51 g, crude, TFA) was obtained as a yellow oil, which was used in the next step.
[0473] Step 3: To a solution of compound 19 (6.51 g, 14.3 mmol, 1.00 eq, TFA) in DCM (100 mL) was added TEA (14.5 g, 143 mmol, 20.0 mL, 10.0 eq) and propionic anhydride (3.75 g, 28.7 mmol, 3.71 mL, 2.00 eq) at 0° C., and the mixture was stirred for 1 hour at 20° C. The reaction mixture was washed with saturated aqueous NaHCO (50.0 mL), H O (50.0 mL), and brine, and the organic layer was dried over anhydrous Na SO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by Prep-HPLC (column: Welch Ultimate XB-CN 250*70*10um; mobile phase: [heptane-ethanol (0.1% NH3H2O)]; B%: 5%-45%, 12 min) to obtain the desired product compound 20 (4.00 g, 10.1 mmol, 70.4% yield) as a yellow solid. LC-MS: rt = 0.56 min; m / z = 395.1, [M+H] + .
[0474] Step 4: Pd / C (400 mg, 10% purity) was added to a solution of compound 20 (4.00 g, 10.1 mmol, 1.00 equiv) in THF (40.0 mL) under N2. The suspension was degassed in vacuo and purged with H2 several times. The mixture was stirred at 15 °C under H2 (15.0 psi) for 12 hours. The reaction mixture was filtered, and the filter cake was washed with MeOH (100 mL), then concentrated under reduced pressure to give a residue. Compound 21 (3.20 g, 8.78 mmol, 86.5% yield) was obtained as a white solid, which was used without further characterization.
[0475] Step 5: EDCI (368 mg, 1.92 mmol, 2.00 equiv) was added to a solution of compound 21 (310 mg, 1.15 mmol, 1.20 equiv) and intermediate A (350 mg, 960 umol, 1.00 equiv) in pyridine (5.00 mL). The mixture was stirred at 15 ° C for 10 hours. The reaction mixture was diluted with H2O (50.0 mL) and extracted with EtOAc (50.0 mL*2). The combined organic layer was washed with saturated NaHCO3 aqueous solution (70.0 mL*2), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain a residue. Compound 22 (400 mg, 649.59 umol, 67.64% yield, N / A purity) was obtained as a white solid. LC-MS: rt=1.00 min; m / z=616.6, [M+H] + .
[0476] Step 6: At 0°C, TFA (1.48 g, 12.9 mmol, 961 uL, 20.0 equiv) was added to a solution of compound 22 (400 mg, 649.umol, 1.00 equiv) in DCM (5.00 mL). The mixture was stirred at 15°C for 2 hours. The reaction mixture was diluted with H2O (10.0 mL), and saturated aqueous NaHCO3 solution was added to adjust the pH to 9. The mixture was extracted with DCM (20 mL*2). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. Compound 23 (288 mg, 558.51 umol, 85.98% yield) was obtained as a yellow solid. LC-MS: rt = 0.90 min; m / z = 516.5, [M+H] + .
[0477] Example 4.1.1—Synthesis of Compound 229
[0478] Step 7: EDCI (37.1 mg, 193 umol, 2.00 equiv) was added to a solution of compound 23 (50.0 mg, 96.9 umol, 1.00 equiv) and 1-cyclopropyl-1H-pyrazole-5-carboxylic acid (22.1 mg, 145 umol, 1.50 equiv) in pyridine (3.00 mL). The mixture was stirred at 15 ° C for 10 hours. The reaction mixture was diluted with H2O (10.0 mL) and extracted with EtOAc (20.0 mL*2). The combined organic layer was washed with saturated NaHCO3 aqueous solution (20 mL*3), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 229 (37.6 mg, 55.9 umol, 57.6% yield, 96.4% purity) was obtained as a white solid. LC-MS: rt = 0.74 min; m / z = 650.4, [M+H] + .
[0479] Compounds 200, 230, 233, 234, 243, 244, 246-249 and 297 were synthesized using similar reaction conditions and appropriate carboxylic acid reagents.
[0480] Example 4.3.2—Synthesis of Compound 200
[0481] To a solution of appropriately substituted compound 23 (50.0 mg, 96.9 umol, 1.00 equiv) and 1-ethyl-1H-pyrazole-5-carboxylic acid (16.7 mg, 119 umol, 1.20 equiv) in pyridine (5.00 mL) was added EDCI (37.1 mg, 193 umol, 2.00 equiv). The mixture was stirred at 25 ° C for 12 hours. The reaction mixture was diluted with saturated NaHCO3 aqueous solution (30.0 mL) and extracted with EtOAc (30.0 mL*3). The combined organic layers were washed with brine (30 mL*3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3um; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 20%-50%, 7min). Compound 200 (31.0 mg, 49.7 umol, 49.8% yield, 100% purity) was obtained as a white solid. LC-MS: rt=0.93 min; m / z=624.4, [M+H] + .
[0482] Example 4.2.3—Synthesis of Compound 246
[0483] To a solution of appropriately substituted compound 23 (50.0 mg, 96.9 umol, 1.00 equiv) and 4-methyl-1,2,5-oxadiazole-3-carboxylic acid (18.6 mg, 145 umol, 1.50 equiv) in pyridine (3.00 mL) was added EDCI (37.1 mg, 193 umol, 2.00 equiv). The mixture was stirred at 15 °C for 10 hours. The reaction mixture was diluted with H2O (10.0 mL) and extracted with EtOAc (20.0 mL*2). The combined organic layers were washed with saturated NaHCO3 aqueous solution (20 mL*3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). Compound 246 (27.3 mg, 41.6 umol, 42.9% yield, 95.4% purity) was obtained as a white solid. LC-MS: rt = 0.76 min; m / z = 626.4, [M+H] + .
[0484] As described in Example 4, It is expressed as: In some embodiments, A in formula (I) or (IA) is represented by A and is an optionally substituted C 3-6 carbocyclic or optionally substituted 5- to 6-membered heterocyclic ring.
[0485] In some embodiments, B in Example 4 is composed of represents and is an optionally substituted 4 to 12 membered heterocyclic ring as described herein.
[0486] Example 5—Synthesis of Compound 201
[0487]
[0488] Step 1: At 25°C, EDCI (200 mg, 1.04 mmol, 2.03 equiv) was added to a solution of intermediate B (140 mg, 519 umol, 1.01 equiv) and compound 21 (B = 1-methylpiperazine) (180 mg, 513 umol, 1.00 equiv) in pyridine (5.00 mL), and the mixture was stirred at 25°C for 12 hours. The mixture was combined with a similar reaction run on a 30.0 mg scale. The residue was diluted with H2O (40.0 mL) and extracted with ethyl acetate (20.0 mL*3). The combined organic layers were washed with brine (20.0 mL*3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3um; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 25%-55%, 7min). Compound 24 (0.150 g, 249 umol, 40.0% yield) was obtained as a white solid. LC-MS: rt=0.76 min; m / z=602.4, [M+H] + .
[0489] Step 2: At 0°C, TFA (454 mg, 3.99 mmol, 295 uL, 20.0 equiv) was added dropwise to a solution of compound 24 (120 mg, 199 umol, 1.00 equiv) in DCM (3.00 mL), and the mixture was stirred at 25°C for 2 hours. The mixture was combined with a similar reaction run on a 30.0 mg scale. The reaction mixture was concentrated under reduced pressure to remove DCM. The residue was diluted with saturated NaHCO3 (20.0 mL) and extracted with ethyl acetate (20.0 mL*3). The combined organic layers were washed with brine (20.0 mL*3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. Compound 25 (110 mg) was obtained as a white solid. LC-MS: rt=0.91 min; m / z=502.5, [M+H] + .
[0490] Step 3: At 25°C, EDCI (61.1 mg, 318 umol, 2.00 equiv) was added to a solution of compound 25 (80.0 mg, 159 umol, 1.00 equiv) and 1-ethyl-1H-pyrazole-5-carboxylic acid (27.0 mg, 192 umol, 1.21 equiv) in pyridine (5.00 mL), and the mixture was stirred at 25°C for 6 hours. The residue was diluted with saturated aqueous NaHCO3 solution (30.0 mL) and extracted with ethyl acetate (30.0 mL*3). The combined organic layer was washed with brine (30.0 mL*3), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by Prep-TLC (SiO2, DCM:MeOH=10:1). The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3um; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 18%-48%, 7min). Compound 201 (35.0 mg, 56.1 umol, 35.1% yield, 100% purity) was obtained as a white solid. LC-MS: rt=0.93 min; m / z=624.5, [M+H] + .
[0491] Example 6—Synthesis of Intermediate D
[0492]
[0493] To a solution of (benzamido)acetic acid (52 g, 290.22 mmol, 1 eq.) in dichloromethane (400 mL) was added EDCI (61.20 g, 319.25 mmol, 1.1 eq.). The mixture was stirred at 25 °C for 2 hours. Water (200 mL) was added to the reaction mixture, and the aqueous phase was extracted with dichloromethane (50 mL*2). The combined organic phases were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated in vacuo to give the product. A mixture of the product with dichloromethane and petroleum ether (V:V=1:4, 500 mL) was stirred at 20 °C for 30 min. The filter cake was obtained as the product, and the filtrate was purified by column chromatography ((SiO2, petroleum ether / ethyl acetate = 50 / 1 to 5 / 1). Intermediate D (42 g, 258.01 mmol, 88.90% yield, 99% purity) was obtained as a yellow solid. LC-MS: rt = 0.93 min; m / z = 624.5, [M+H] + . 1H NMR: (400MHz, CDCl3) δ8.01-7.99(m,2H),7.59-7.52(m,1H),7.51-7.48(m,2H),4.43(s,2H).
[0494] Example 7—Synthesis of Intermediate E
[0495]
[0496] Step 1: At 0°C, to a solution of 4-bromo-3-fluorobenzaldehyde (115 g, 566.48 mmol, 1 eq.) in THF (1000 mL), TMSCF3 (96.66 g, 679.78 mmol, 1.2 eq.) was added, followed by TBAF (1 M, 11.33 mL, 0.02 eq.). The mixture was stirred at 20°C for 1 hour. At 10°C, HCl (3 M, 283.24 mL, 1.5 eq.) was added, and the mixture was stirred at 20°C for 12 hours. MTBE (200 mL) was added to the mixture, and the aqueous phase was extracted with MTBE (100 mL). The organic phase was washed with brine (100 mL), dried over Na2SO4, filtered, and then concentrated in vacuo to give a crude product. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 50 / 1). Compound 26 (150 g, 533.47 mmol, 94.17% yield, 97.1% purity) was obtained as a colorless oil. LC-MS: rt = 0.98 min; m / z = 271.0, [MH] - . 1 HNMR: (400MHz, CDCl3) δ: 7.62-7.58 (m, 1H), 7.32-7.29 (m, 1H), 7.16 (d, J = 8.4Hz, 1H), 5.04-5.01 (m, 1H), 2.78-2.77 (d, J = 3.6Hz, 1H).
[0497] Step 2: DMP (139.82 g, 329.64 mmol, 102.06 mL, 1.2 eq.) was added to a solution of compound 26 (75 g, 274.70 mmol, 1 eq.) in dichloromethane (700 mL) at 0 °C. The mixture was stirred at 20 °C for 4 hours. H2O (500 mL) was added to the reaction mixture and then filtered. The filtrate was washed with saturated NaHCO3 (200 mL), saturated Na2SO3 (100 mL*2), and brine (100 mL) in sequence. The organic phase was dried over Na2SO4, filtered and concentrated in vacuo to give the crude product. The crude product 27 was used in the next step without purification.
[0498] Step 3: To a solution of TiCl4 (60.89 g, 321.03 mmol, 1.5 equivalents) in THF (600 mL) at -10°C, a THF solution (100 mL) of compound 27 (58 g, 214.02 mmol, 1 equivalent) was added. To the mixture was added a THF solution (100 mL) of intermediate D (41.39 g, 256.82 mmol, 1.2 equivalents) at -10°C. The mixture was stirred at -10 to 0°C for 30 min. Pyridine (33.86 g, 428.03 mmol, 34.55 mL, 2 equivalents) was added at 0°C, and the mixture was stirred at 20°C for 12 hours. H2O (200 mL) was added to the mixture, and the aqueous phase was extracted with ethyl acetate (100 mL*2). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered and concentrated in vacuo to give a crude product. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 20 / 1). Compound 28 (54 g, 130.39 mmol, 60.92% yield, 100% purity) was obtained as a yellow solid. LC-MS: rt = 1.09 min; m / z = 414.1, [M+H] + . 1 H NMR: (400MHz, CDCl3) δ8.21-8.19(m,2H),7.70-7.66(m,2H),7.59-7.57(m,2H),7.17-7.15(m,1H),7.07-7.05(m,1H).
[0499] Step 4: A MeOH solution (100 mL) of compound 28 (40 g, 96.58 mmol, 1 equivalent) was stirred at 50 ° C for 4 hours. The mixture was concentrated in vacuo to give the product. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 1 to 5 / 1). Compound 29 (40 g, 88.75 mmol, 91.89% yield, 99% purity) was obtained as a white solid. 1 HNMR: (400MHz, CDCl3) δ8.46 (s, 1H), 7.85-7.83 (m, 2H), 7.64-7.52 (m, 4H), 7.12-7.10 (d, J = 8.8Hz, 1H), 7.01-6.81 (d, J = 8.0Hz, 1H), 3.60 (s, 3H).
[0500] Step 5: To a solution of compound 29 (10 g, 22.41 mmol, 1 eq.) in MeOH (100 mL) was added PtO2 (1.00 g, 4.40 mmol, 1.96 e-1 eq.) under N2. The suspension was degassed in vacuo and purged with H2 several times. The mixture was stirred at 20 °C under H2 (50 psi) for 16 hours. The mixture was filtered, and the filtrate was concentrated in vacuo to give the crude product. The crude product was used in the next step without purification. Compound 30 (10 g, crude) was obtained as a white solid. LC-MS: rt = 1.10 min; m / z = 452.0, [MH] - .
[0501] Step 6: A solution of compound 30 (10 g, 22.01 mmol, 1 eq.) in HCl (6 M, 98.67 mL, 26.89 eq.) and AcOH (51.80 g, 862.60 mmol, 49.33 mL, 39.18 eq.) was stirred at 120 °C for 12 hours. The reaction mixture was concentrated in vacuo to give the crude product. The crude product was used in the next step without purification. Compound 31 (8 g, crude, HCl) was obtained as a yellow oil. LC-MS: rt = 0.70 min; m / z = 330.1, [M+H] + .
[0502] Step 7: To a solution of compound 31 (8 g, 21.83 mmol, 1 eq, HCl) in THF (90 mL) was added a solution of K2CO3 (12.07 g, 87.30 mmol, 4 eq) in H2O (20 mL). Boc2O (7.15 g, 32.74 mmol, 7.52 mL, 1.5 eq) was added to the mixture. The mixture was stirred at 20 °C for 12 hours. The pH value of the mixture was adjusted to 4 with HCl (1 M), and then extracted with ethyl acetate (50 mL*2). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated in vacuo to give a crude product. The crude product was used in the next step without purification. Compound 32 (9 g, crude) was obtained as a yellow oil.
[0503] Step 8: TMSCHN2 (2M, 11.51 mL, 1.1 eq.) was added dropwise to a solution of compound 32 (9 g, 20.92 mmol, 1 eq.) in dichloromethane (150 mL) and MeOH (15 mL). The mixture was stirred at 20 ° C for 2 hours. The mixture was concentrated in vacuo to obtain a crude product. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate=100 / 1 to 5 / 1). Compound 33 (9 g, 19.33 mmol, 92.39% yield, 95.4% purity) was obtained as a light yellow oil.
[0504] Step 9: To a mixture of compound 33 (12.5 g, 28.14 mmol, 1 eq.), diphenylmethaniline (7.65 g, 42.21 mmol, 7.08 mL, 1.5 eq.) and Cs2CO3 (18.34 g, 56.28 mmol, 2 eq.) in dioxane (200 mL) was added Pd2(dba)3 (1.29 g, 1.41 mmol, 0.05 eq.) and Xantphos (1.63 g, 2.81 mmol, 0.1 eq.). The mixture was stirred at 100°C for 14 hours. The mixture was filtered and the filtrate was concentrated in vacuo to give the crude product. The crude product was used in the next step without purification. Compound 34 (20 g, crude) was obtained as a dark brown oil. LC-MS: rt = 1.12 min; m / z = 545.3, [M+H] + .
[0505] Step 10: To a solution of compound 34 (20 g, 36.73 mmol, 1 eq.) in THF (150 mL), citric acid (10 M, 140.00 mL, 38.12 eq.) was added. The mixture was stirred at 20 ° C for 16 hours. The mixture was extracted with ethyl acetate (150 mL * 2), and the organic layer was washed with saturated NaHCO3 (150 mL), brine (100 mL), dried over Na2SO4, filtered, and concentrated in vacuo to give a crude product. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 100 / 1 to 3 / 1). Intermediate E (5 g, 12.90 mmol, 35.11% yield, 98.1% purity) was obtained as a yellow oil. LC-MS: rt = 0.92 min; m / z = 281.1, [M + H-boc] +1 H NMR: (400MHz, CDCl3) δ7.02-6.98(m,1H),5.95-6.88(m,1H),6.77-6.75(m,1H),5.18 -5.04(m,1H),4.87-4.81(m,1H),3.86-3.79(m,1H),3.71-3.68(m,3H),1.43(s,9H).
[0506] Example 8. Exemplary Scheme - Synthesis of Compounds 350-357
[0507]
[0508] Step 1: To a solution of intermediate E (500 mg, 1.31 mmol, 1.00 equiv) and Cbz-amino acid (518 mg, 1.71 mmol, 1.30 equiv) in pyridine (10.0 mL) was added EDCI (756 mg, 3.94 mmol, 3.00 equiv) at 25°C for 2 hours. 40.0 mL of H2O was added to the reaction mixture and extracted with EtOAc 100 mL (50.0 mL*2). The combined organic layer was washed with saturated NaHCO3 aqueous solution 100 mL*2, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (basic conditions, column: Welch Ultimate XB-CN 250*50*10um; mobile phase: [hexane-EtOH (0.1% NH3·H2O)]; B%: 1%-40%, 15 min). Compound 35 (400 mg, 600 umol, 45.7% yield) was obtained as a white solid. LC-MS: rt = 1.08 min; m / z = 566.3, [M+H-Boc] + .
[0509] Step 2: Under N2 atmosphere, Pd / C (40.0 mg, 10.0% purity) was added to a solution of compound 35 (400 mg, 600 umol, 1.00 equiv.) in DCM (5.00 mL). The suspension was degassed and purged with H2 3 times. The mixture was stirred at 25 °C under H2 (15 Psi) for 2 hours. The reaction mixture was filtered, the filter cake was washed with 100 mL MeOH, and concentrated under reduced pressure to give a residue. Compound 36 (319 mg, 600 umol, 99.8% yield) was obtained as a white solid. LC-MS: rt = 0.84 min; m / z = 554.1, [M+H] + .
[0510] Step 3: EDCI (345 mg, 1.80 mmol, 3.00 equiv) was added to a solution of compound 36 (319 mg, 600 umol, 1.00 equiv) and 1-ethyl-1H-pyrazole-5-carboxylic acid (126 mg, 900 umol, 1.50 equiv) in pyridine (5.00 mL). The mixture was stirred at 25 ° C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with EtOAc (30.0 mL*3). The combined organic layer was washed with saturated NaHCO3 (30.0 mL*2) aqueous solution, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. Compound 37 (340 mg, 520 umol, 86.6% yield) was obtained as a white solid. LC-MS: rt = 0.99 min; m / z = 654.5, [M+H] + .
[0511] Step 4: At 0°C, a solution of compound 37 (340 mg, 520 umol, 1.00 equiv) in MeOH (2.00 mL) and THF (2.00 mL) was added with a solution of NaOH (83.2 mg, 2.08 mmol, 4.00 equiv) in H2O (1.00 mL). The mixture was stirred at 25°C for 2 hours. The reaction mixture was diluted with H2O (10.0 mL), and 1 M HCl was added to adjust the pH to 2. The mixture was extracted with (20.0 mL*3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. Compound 38 (320 mg, 500 umol, 96.1% yield) was obtained as a yellow solid. LC-MS: rt = 0.59 min; m / z = 640.4, [M+H] + .
[0512] Step 5: At 0°C, DIEA (161 mg, 1.25 mmol, 217 uL, 5.00 equiv) and T3P (477 mg, 750 umol, 446 uL, 50.0% purity, 3.00 equiv) were added to a solution of compound 38 (160 mg, 250 umol, 1.00 equiv) and 1-methylpiperazine (37.5 mg, 375 umol, 41.6 uL, 1.50 equiv) in DCM (5.00 mL). The mixture was stirred at 25°C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with DCM (30.0 mL*3). The combined organic layers were washed with saturated NH4Cl (30.0 mL*2) aqueous solution, dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. Compound 39 (B = 1-methylpiperazine) (180 mg, 249 umol, 99.7% yield) was obtained as a yellow solid. LC-MS: rt = 0.84 min; m / z = 722.5, [M+H] + .
[0513] Step 6: At 0°C, TFA (568 mg, 4.99 mmol, 369 uL, 20.0 equiv) was added to a solution of compound 39 (B = 1-methylpiperazine) (180 mg, 249 umol, 1.00 equiv) in DCM (5.00 mL). The mixture was stirred at 25°C for 2 hours. The reaction mixture was diluted with H2O (10.0 mL) and saturated aqueous NaHCO3 solution was added to adjust the pH to 9. The mixture was extracted with (20.0 mL*2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. Compound 40 (B = 1-methylpiperazine) (150 mg, 241 umol, 96.7% yield) was obtained as a white solid. LC-MS: rt = 0.77 min; m / z = 622.3, [M+H] + .
[0514] Step 7: TEA (45.5 mg, 450 mol, 62.6 uL, 2.00 equiv) and propanoylpropanoate (37.6 mg, 289 umol, 37.3 uL, 1.20 equiv) were added to a solution of compound 40 (B = 1-methylpiperazine) (140 mg, 225 umol, 1.00 equiv) in DCM (5.00 mL) at 0°C. The mixture was stirred at 25°C for 2 hours. The reaction mixture was diluted with H2O (30.0 mL) and extracted with EtOAc (30.0 mL*3). The combined organic layers were washed with saturated aqueous NaHCO3 (30.0 mL*2), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue.
[0515] The residue was purified by SFC (column: DAICEL CHIRALPAK IE (250 mm*30 mm, 10 um); mobile phase: [hexane-IPA]; B%: 25%-25%, 15 min) to give compound 350. The residue was further purified by SFC (column: DAICELCHIRALCEL OD-H (250 mm*30 mm, 5 um); mobile phase: [0.1% NH3H2O ETOH]; B%: 15%-15%, 2.2; 90 min, Rt=1.143, 1.191 min) to give compound 352. The residue was further purified by SFC (column: DAICELCHIRALPAK AD-H (250 mm*30 mm, 5 um); mobile phase: [0.1% NH3H2O IPA]; B%: 20%-20%, 5.2 min; 70 min, Rt=1.216, 1.348 min) to give compound 354. The residue was further purified by SFC (column: DAICELCHIRALPAK AD-H (250 mm*30 mm, 5 um); mobile phase: [0.1% NH3H2O IPA]; B%: 20%-20%, 5.2 min; 40 min, Rt=1.324 min) to give compound 356.
[0516] Compound 350 (9.10 mg, 12.4 umol, 5.53% yield, 92.7% purity) was obtained as a white solid. LC-MS: rt = 0.97 min; m / z = 678.5, [M+H] + . 1H NMR: (400MHz, CDCl3) δ8.48-8.44(t,J=8.8Hz,1H),8.35-8.31(m,1H),7.63(d,J=2.0Hz,1H),7.40(s,1H),7.25-7.19(m,2H ),6.73(d,J=2.0Hz,1H),6.34(d,J=9.6Hz,1H),5.80-5.75(t,J=10Hz,1H),4.99-4.96(m,1H),4.76-4.70(m,2H),4.09-3.9 8(m,1H),3.70-3.65(m,1H),3.57-3.53(m,1H),3.47-3.42(m,1H),2.40-2.35(m,3H),2.27(s,3H),2.13-2.00(m,1H),1.59 -1.55(t,J=7.2Hz,3H),1.39(s,3H),1.31-1.27(t,J=8.0Hz,3H),1.07-0.91(m,3H),0.62-0.66(m,4H),0.54-0.36(m,4H).
[0517] Compound 352 (22.67 mg, 31.2 umol, 13.8% yield, 93.4% purity) was obtained as a white solid. LC-MS: rt = 0.98 min; m / z = 678.4, [M+H] + . 1 H NMR: (400MHz, CDCl3) δ8.29-8.25(m,2H),7.48(d,J=2.0Hz,1H),7.17-7.08(m,3H),6.59(d,J=2. 0Hz,1H),6.17-6.15(m,1H),5.72-5.67(t,J=9.6Hz,1H),4.90-4.87(m,1H),4.60-4.54(m,2H),4 .07-3.99(m,1H),3.78-3.63(m,3H),2.48-2.39(m,3H),2.31(s,3H),2.02-1.83(m,4H),1.43-1. 39(t,J=6.8Hz,3H),1.28-1.24(m,1H),0.91-0.80(m,5H),0.67-0.52(m,4H),0.42-0.23(m,4H).
[0518] Compound 354 (16.3 mg, 23.6 umol, 10.5% yield, 98.4% purity) was obtained as a white solid. LC-MS: rt = 0.98 min; m / z = 678.4, [M+H] + .1 H NMR: (400MHz, CDCl3) δ8.39(s,1H),8.28-8.24(t,J=8.4Hz,1H),7.49(d,J=2.0Hz,1H),7.30-7.27(m,1H),7.09- 7.06(m,2H),6.65(d,J=2.0Hz,1H),6.25(d,J=9.2Hz,1H),5.75-5.70(t,J=9.6Hz,1H),4.94-4.91(m,1H),4.65-4 .52(m,2H),4.06-3.97(m,1H),3.81-3.71(m,2H),3.64-3.58(m,1H),2.47-2.39(m,3H),2.32(s,3H),1.96-1.82 (m,3H),1.44-1.40(t,J=7.2Hz,3H),1.31-1.25(m,2H),0.88-0.76(m,5H),0.67-0.49(m,4H),0.43-0.17(m,4H).
[0519] Compound 356 (11.94 mg, 17.4 umol, 7.76% yield, 99.2% purity) was obtained as a white solid. LC-MS: rt = 0.82 min; m / z = 678.6, [M+H] + . 1 H NMR: (400MHz, CD3CN) δ8.76(s,1H),7.99-7.94(t,J=8.4Hz,1H),7.48(d,J=1.6Hz,1H),7.39-7.31(m,1H),7.26- 7.18(m,2H),7.06(d,J=9.6Hz,1H),6.85(d,J=2.0Hz,1H),5.64-5.59(t,J=10.8Hz,1H),4.93-4.89(m,1H),4.57 -4.51(m,2H),4.13-4.03(m,1H),3.82(s,2H),3.56(s,1H),2.60-2.55(m,2H),2.52(s,3H),2.20-2.15(m,2H),1 .45-1.37(m,3H),1.27-1.24(m,2H),1.00-1.11(m,3H),0.93-0.82(m,4H),0.51-0.36(m,4H),0.29-0.22(m,4H).
[0520] Compounds 351, 353, 355 and 357 were synthesized similarly using (R)-1,2-dimethylpiperazine as B in Example 8 and purified.
[0521] In some embodiments, B of Example 8 is composed of represents and is an optionally substituted 4 to 12 membered heterocyclic ring as described herein.
[0522] Example 9: IL-17A / A HEK-Blue Cell Assay
[0523] The HEK-Blue IL-17 reporter cell line (Fisher #NC1408637) was used for the cell-based IL-17A / A inhibition assay. Cells were cultured and prepared for the assay according to the manufacturer's instructions. This cell line consists of HEK293 cells engineered to express IL-17RA, IL-17RC, and the ActI adaptor molecule, which, when stimulated by IL-17A / A, activates the NFκB promoter and drives expression of the recombinant secretory alkaline phosphatase (SEAP) protein. The cell culture medium was then added to the developing reagent (Quanti-Blue Substrate, Fisher #NC9711613) and the A 630 Read at.
[0524] Compounds were titrated into DMSO to a final compound top concentration of 10 uM and added to cells immediately prior to the addition of IL-17A / A (Genscript #Z03228). Cells, compounds, and IL-17A / A were then incubated for 20 hours before the media was removed for SEAP analysis. The resulting inhibition curves were then analyzed using the Dotmatics screening protocol and IC was determined using a 4-parameter nonlinear fit. 50 DMSO was added to a common final concentration of 0.1% to optimize background. Table 1 provides IL-17A / A inhibition data for selected compounds.
[0525] Example 10: IL-17A / FHEK-Blue Cell Assay
[0526] The HEK-Blue IL-17 reporter cell line (Fisher #NC1408637) was used for the cell-based IL-17A / F inhibition assay. Cells were cultured and prepared for the assay according to the manufacturer's instructions. This cell line consists of HEK293 cells engineered to express IL-17RA, IL-17RC, and the ActI adaptor molecule, which in combination activate the NFκB promoter and drive expression of the recombinant secretory alkaline phosphatase (SEAP) gene protein when stimulated with IL-17A / A. The cell culture medium was then added to the developing reagent (Quanti-Blue Substrate, Fisher #NC9711613) and the cells were grown in A 630 Read at.
[0527] Compounds were titrated in DMSO and immediately added to cells, followed by IL-17A / A (custom made by R&D Systems, unlabeled IL-17A / F + BSA as carrier protein). Cells, compounds, and IL-17A / A were then incubated for 20 hours, after which the media was removed for SEAP analysis. The resulting inhibition curves were then analyzed using the Dotmatics screening protocol, and IC was determined using a 4-parameter nonlinear fit. 50 DMSO was added to a general final concentration of 0.1% to optimize background. Table 1 provides IL-17A / F inhibition data for selected compounds. Table 1 includes pIC values for IL-17A / A and IL-17A / F inhibition by selected compounds 50 Value; pIC 50 Compounds with 8 or more are A; 8>B > 7 is B; 7>C > 5. Table 1 also includes synthesis and spectral data for the claimed IL-17 modulators.
[0528] Table 1 - Bioassay inhibition data and spectral data for compounds 200-363
[0529]
[0530]
[0531]
[0532]
[0533]
[0534]
[0535]
[0536]
[0537]
[0538]
[0539]
[0540]
[0541]
[0542]
[0543]
[0544]
[0545]
[0546]
[0547]
[0548]
[0549]
[0550]
[0551]
[0552]
[0553]
[0554]
[0555]
[0556]
[0557]
[0558]
[0559]
[0560]
[0561]
[0562]
[0563]
[0564]
[0565]
[0566]
[0567]
[0568]
[0569]
[0570]
[0571]
[0572]
[0573]
[0574]
[0575]
[0576]
[0577]
[0578]
[0579] Example 11: Comparison of Selected IL-17 Modulators with Reference Compound AM
[0580] Microsome stability studies
[0581] Preparation of test compound and control working solutions. 5 μL of compound and control stock solutions (10 mM in dimethyl sulfoxide (DMSO)) were diluted with 495 μL of acetonitrile (ACN).
[0582] Preparation of NADPH cofactor. Weigh an appropriate amount of NADPH powder and dilute it into 10mM MgCl2 solution (working solution concentration: 10mM, final concentration of the reaction system: 1mM). Materials: NADPH powder: β-nicotinamide adenine dinucleotide phosphate reduced form, tetrasodium salt; NADPH·4Na (supplier: Chem-Impex International, catalog number: 00616).
[0583] Preparation of liver microsomes. Prepare microsome working solutions of appropriate concentrations in 100 mM potassium phosphate buffer. Materials: Human liver microsomes (HLM) Catalog No. 452117 and Lot No. 38295 (Corning); SD rat liver microsomes (RLM) Catalog No. R1000 and Lot No. 1910100 (Xenotech).
[0584] Stop solution preparation: Cold (4°C) acetonitrile (ACN) containing 200 ng / mL tolbutamide and 200 ng / mL labetalol as internal standard (IS) was used as the stop solution.
[0585] Assay Method. Empty incubation plates (T60 and NCF60) were preheated for 10 min prior to use. Liver microsomes were diluted to 0.56 mg / mL in 100 mM phosphate buffer. 445 uL of microsome working solution (0.56 mg / mL) was transferred to the preheated 'incubation' plates T60 and NCF60, which were then preincubated at 37°C for 10 min with constant shaking. 54 μL of liver microsomes were transferred to the blank plate, and 6 μL of NAPDH cofactor was added to the blank plate, followed by 180 μL of quenching solution. 5 μL of compound working solution (100 μm) was added to the 'incubation' plates (T60 and NCF60) containing microsomes and mixed well 3 times. 50 uL of buffer was added to the NCF60 plate and mixed well 3 times. Start timing; incubate the plates at 37°C for 60 min with shaking. In the 'quench' plate T0, add 180 μL of quench solution and 6 μL of NAPDH cofactor. Cool the plate to prevent evaporation. Mix the T60 plate thoroughly 3 times and immediately remove 54 μL of the mixture to the 'quench' plate at the 0 min time point. Then add 44 μL of NAPDH cofactor to the incubation plate (T60). Start timing; incubate the plate at 37°C for 60 min while shaking. Final concentration of each component in the incubation medium: microsomes (0.5 mg protein / mL); test compound (1 μM); control compound (1 μM); ACN (0.99%); and DMSO (0.01%). At 5, 15, 30, 45, and 60 min, 180 μL of quenching solution was added to the ‘Quench’ plate, mixed once, and then 60 μL of sample was continuously transferred from the T60 plate to the ‘Quench’ plate at each time point. For the NCF60 plate, mixed once, and at the 60 min time point (start time 1:00:00 and end time 0:00:00), 60 μL of sample was transferred from the NCF60 incubation plate to the ‘Quench’ plate containing the quenching solution. The reaction plate incubation times are provided in Table 2.1.
[0586] Table 2.1: Reaction plate incubation
[0587]
[0588] All sample plates were shaken for 10 min and then centrifuged at 4000 rpm for 20 min at 4 °C. 80 μL of supernatant was transferred to 240 μL of HPLC water and mixed for 10 min using a plate shaker. Each bioassay plate was sealed and shaken for 10 min before LC-MS / MS analysis. First-order kinetics were used to calculate half-life and CL int(mic) (μL / min / mg), as shown in Table 2.6.
[0589] Pharmacokinetics in rats
[0590] PO formulations. Weigh the appropriate amount of test article and mix with an appropriate volume of vehicle to obtain a clear solution or homogenous suspension, either by waterbath vortexing or sonication. Dose animals within four hours of formulation preparation. Take a formulation sample from each formulation solution or suspension, transfer to a 1.5 mL polypropylene microcentrifuge tube, and verify the dose by LC / UV or LC-MS / MS.
[0591] Dosing. For PO dosing, the dosage formulation is administered by oral gavage.
[0592] Blood collection. Each blood collection (approximately 0.2 mL per time point) was collected from the carotid artery cannula (CAC) of each animal into pre-cooled commercial EDTA-K2 tubes as an anticoagulant and then placed on wet ice until centrifugation. Blood samples were centrifuged at approximately 4°C and 3,200g for 10 min to process plasma. Plasma was collected separately, and a certain amount of rat plasma was transferred to a pre-labeled 96-well plate or polypropylene tube, quickly frozen on dry ice and stored at -60°C or lower until LC-MS / MS analysis. After the terminal collection, all plasma was stored in a refrigerator at approximately -80°C until final analysis.
[0593] Plasma concentration versus time data were plotted and analyzed by non-compartmental methods using Phoenix WinNonlin 6.3 software program. The POAUC calculation method used was linear / log trapezoidal, and the values for this method are reported in Table 2.6. Trapezoids: before TMax (linear); after Tmax (logarithmic). Partial area interpolation: before TMax (linear); after Tmax (logarithmic).
[0594] Table 2.2 provides the study design for determining pharmacokinetics in rats. Table 2.3 provides the dosing schedule for PK analysis. Table 2.4 provides the sample collection schedule.
[0595] Table 2.2. Rat pharmacokinetic study design
[0596]
[0597] Is Cassette: True indicates that the set of cassette compounds were administered. False indicates that a single compound was administered. Is Diff: True indicates that the cassette compounds were administered and the dose level of each compound was different. False indicates that the dose level of each compound or single compound was administered was the same.
[0598] Table 2.3. Pharmacokinetic dose table in rats
[0599] Group sky Time (h) 01 1 0 02 1 0
[0600] Table 2.4. Rat pharmacokinetic sample collection table
[0601]
[0602] Table 2.5 provides a list of selected IL-17 modulators disclosed herein for comparative studies with reference compounds A to M.
[0603] Table 2.6 provides microsomal stability data and rat pharmacokinetic data for selected IL-17 modulators relative to reference compounds A to M. The data demonstrate that the selected IL-17 modulators have enhanced microsomal stability and rat pharmacokinetics relative to reference compounds A to M.
[0604] Table 2.5. List of comparative compounds
[0605]
[0606]
[0607]
[0608]
[0609]
Claims
1. A compound represented by the structure of formula I: or a pharmaceutically acceptable salt thereof, wherein: A is selected from C 3-6 Carbocyclic and 5- to 6-membered heterocyclic rings, any of which is optionally substituted with one or more substituents independently selected from (a), (b) and (c): (a) Halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; (b)C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 、-NO2、-CN、C 3-6 Carbocyclic and 3- to 6-membered heterocyclic rings, each C 3-6 The carbocyclic and 3- to 6-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and (c)C 3-6 Carbon ring, the C 3-6 The carbocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C 1-4 Alkyl, C 1-4 Haloalkyl, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN; R 1 Selected from hydrogen, halogen, -OR 12 、-N(R 12 )2. -C(O)R 12 、-C(O)OR 12 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 12 、-N(R 12 )2. -C(O)R 12 、-C(O)OR 12 , -NO2 and -CN; R 2 Selected from -N(R A )C(O)(R B ) and -N(R C )C(O)N(R D )(R E ); is selected from a 4- to 12-membered heterocyclic ring, the 4- to 12-membered heterocyclic ring being optionally substituted by one or more substituents, The substituents are independently selected from: Halogen, -OR 13 、-N(R 13 )2. -C(O)R 13 、-C(O)OR 13 , -NO2, -CN, and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2. -C(O)R 13 、-C(O)OR 13 , -NO2 and -CN; R 3 Selected from halogen, -OR 14 、-N(R 14 )2. -C(O)R 14 、-C(O)OR 14 、-NO2、-CN、C 1-6 Alkyl and C 3-6 A carbon ring, in which each C 1-6 Alkyl and C 3-6 The carbocyclic ring is optionally substituted with one or more substituents independently selected from halogen, -OR 14 、-N(R 14 )2. -C(O)R 14 、-C(O)OR 14 , -NO2 and -CN; R A Selected from hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 15 、-N(R 15 )2. -C(O)R 15 、-C(O)OR 15 , -NO2 and -CN; R B Selected from: C 1-6 Alkyl, the C 1-6 Alkyl is optionally substituted with one or more substituents independently selected from: halogen, -OR 16 , -N(R 16 )2, -C(O)R 16 , -C(O)OR 16 , -N(R 16 )C(O)OR 16 , -NO2, -CN; C 3-6 carbocyclic and 5- to 6-membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 , -C(O)OR 16 , -NO2 and -CN; and C 3-6 A carbocyclic ring or a 4- to 6-membered heterocyclic ring, each of which is optionally substituted by one or more substituents independently selected from: Halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN; R C Selected from hydrogen and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 17 、-N(R 17 )2. -C(O)R 17 、-C(O)OR 17 , -NO2 and -CN; R D Selected from C 1-6 Alkyl and C 3-6 carbocyclic ring, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 , -NO2 and -CN; R E Selected from hydrogen, C 1-6 Alkyl and C 3-6 carbocyclic ring, any of which is optionally substituted with one or more substituents, The substituents are independently selected from: halogen, -OR 19 、-N(R 19 )2. -C(O)R 19 、-C(O)OR 19 , -NO2 and -CN; R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 and R 19 Each occurrence is independently selected from: hydrogen; C 1-6 Alkyl, optionally substituted with one or more substituents independently selected from: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, each C 3-10 The carbocyclic and 3- to 10-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN; and C 3-10 Carbocyclic and 3- to 10-membered heterocyclic rings, optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OH, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O and -CN; and n is selected from 0, 1, 2, 3 and 4.
2. The compound or salt of claim 1, wherein n is 1.
3. The compound or salt of claim 1 or claim 2, wherein each R 3 are independently selected from fluorine, chlorine, -OR 14 、-N(R 14 )2.-CN, C 1-3 Alkyl and C 1-3 Halogenated alkyl.
4. The compound or salt of claim 3, wherein each R 3 Selected from fluorine.
5. The compound or salt according to any one of claims 1 to 4, wherein formula (I) is represented by formula (IA):
6. The compound or salt of any one of claims 1 to 5, wherein R 1 Selected from hydrogen, halogen, -OR 12 、-N(R 12 )2.-CN, C 1-3 Alkyl and C 1-3 Halogenated alkyl.
7. The compound or salt of claim 6, wherein R 1 Selected from methyl, ethyl, propyl and trifluoromethyl.
8. The compound or salt of claim 7, wherein R 1 Selected from methyl.
9. The compound or salt of claim 7, wherein R 1 Selected from trifluoromethyl.
10. The compound or salt of any one of claims 1 to 9, wherein A is selected from saturated C 3-6 carbocyclic and 5-membered heteroaryl, any of which is optionally substituted with one or more substituents independently selected from: (a), (b) and (c): (a) Halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; (b)C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 、-NO2、-CN、C 3-6 Carbocyclic and 5- to 6-membered heterocyclic rings, each C 3-6 The carbocyclic and 5- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and (c)C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
11. The compound or salt of claim 10, wherein A is selected from saturated C 3-6 carbocyclic ring, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 11 、-N(R 11 )2.-CN, C 1-3 Alkyl and C 1-3 Halogenated alkyl.
12. The compound or salt of claim 11, wherein A is cyclopropyl, optionally substituted with halogen, C 1-3 Alkyl and C 1-3 Haloalkyl substitution.
13. The compound or salt of claim 12, wherein A is 14. The compound or salt of claim 10, wherein A is a 5-membered heteroaryl, the 5-membered heteroaryl being optionally substituted with one or more substituents independently selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2, -CN; and 5 to 6 membered heterocyclic rings, each of which is optionally substituted by one or more substituents selected from: Halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and C 3-6 carbocyclic rings, each of which is optionally substituted by one or more substituents selected from: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
15. The compound or salt of claim 14, wherein A is selected from pyrazole, imidazole, oxazole, isoxazole, oxadiazole, triazole, tetrazole, any of which is optionally substituted with one or more substituents independently selected from: C 1-3Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 11 and a 5- to 6-membered saturated heterocyclic ring, each of which is optionally substituted by one or more substituents selected from the group consisting of halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、C(O)OR 11 , -NO2 and -CN; and Saturated C 3-6 Carbocyclic ring, the saturated C 3-6 The carbocyclic ring is optionally substituted with one or more substituents selected from the group consisting of: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
16. The compound or salt of claim 15, wherein A is selected from pyrazole and oxadiazole, each of which is optionally substituted with one or more substituents independently selected from C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkyl-OR 11 and C substituted by a 5- to 6-membered saturated heterocyclic ring 1-3 alkyl.
17. The compound or salt of claim 16, wherein A is selected from pyrazole and oxadiazole, each of which is optionally substituted with methyl, ethyl, propyl and isopropyl.
18. The compound or salt of claim 17, wherein A is selected from:
19. The compound or salt of claim 16, wherein A is selected from pyrazole and oxadiazole, each of which is optionally substituted with C 1-3 Haloalkyl and C 1-3 Alkyl-OR 11 replace.
20. The compound or salt of claim 19, wherein A is selected from:
21. The compound or salt of claim 16, wherein A is selected from pyrazole and oxadiazole, each of which is optionally replaced by C 1-3 Alkyl substituted, the C 1-3 The alkyl group is substituted with a 5- to 6-membered saturated heterocyclic ring.
22. The compound or salt of claim 21, wherein A is 23. The compound or salt of claim 15, wherein A is selected from pyrazole and oxadiazole, each of which is optionally substituted with one or more substituents independently selected from saturated C 3-6 Carbocyclic ring, the saturated C 3-6 The carbocyclic ring is optionally substituted with one or more substituents selected from the group consisting of: halogen, -OR 11 、-N(R 11 )2. -C(O)R 11 、-C(O)OR 11 , -NO2 and -CN.
24. The compound or salt of claim 23, wherein A is selected from pyrazole and oxadiazole, each of which is optionally substituted with cyclopropyl, wherein the cyclopropyl is optionally substituted with fluoro or chloro.
25. The compound or salt of claim 24, wherein A is selected from:
26. The compound or salt of any one of claims 1 to 25, wherein R 2 Selected from -N(R C )C(O)N(R D )(R E ),in: R C Selected from hydrogen; R D Selected from C 1-6 Alkyl and saturated C 3-6 carbocyclic ring, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 18 、-N(R 18 )2. -C(O)R 18 、-C(O)OR 18 , -NO2 and -CN; and R E Selected from C 1-6 Alkyl and saturated C 3-6 carbocyclic ring, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 19 、-N(R 19 )2. -C(O)R 19 、-C(O)OR 19 , -NO2 and -CN.
27. The compound or salt of claim 26, wherein R D Selected from C 1-3 Alkyl and cyclopropyl, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 18 、-N(R 18 )2, -NO2 and -CN; and R E Selected from C 1-3 alkyl.
28. The compound or salt of claim 27, wherein R 2 Selected from:
29. The compound or salt of any one of claims 1 to 25, wherein R 2 Selected from -N(R A )C(O)(R B ),in: R A Selected from hydrogen, C 1-6 Alkyl and C 1-6 Haloalkyl; R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -N(R 16 )C(O)OR 16 、-NO2、-CN;C 3-6 carbocyclic and 5- to 6-membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 16 , -N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN; and 4 to 6 membered heterocyclic ring, the 4 to 6 membered heterocyclic ring is optionally substituted by one or more substituents independently selected from: halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN.
30. The compound or salt of claim 29, wherein R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 、-NO2、-CN、C 3-6 Carbocyclic and 5- to 6-membered heterocyclic rings, each C 3-6 The carbocyclic and 5- to 6-membered heterocyclic rings are optionally substituted by one or more substituents independently selected from the group consisting of halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN.
31. The compound or salt of claim 30, wherein R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 、-N(R 16 )C(O)OR 16 , -NO2 and -CN.
32. The compound or salt of claim 31, wherein R A is hydrogen; and R B Selected from C 1-6 Alkyl and C 1-6 Halogenated alkyl.
33. The compound or salt of claim 32, wherein R 2 Selected from:
34. The compound or salt of claim 31, wherein R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 and N(R 16 )C(O)OR 16 .
35. The compound or salt of claim 34, wherein R 2 Selected from:
36. The compound or salt of claim 31, wherein R A is hydrogen; and R B is optionally -OR 16 Substituted C 1-6 Alkyl, where R 16 Is -OC 1-6 Alkyl substituted C 1-6 alkyl.
37. The compound or salt of claim 36, wherein R 2 yes 38. The compound or salt of claim 30, wherein R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of C 3-6 carbocyclic and 5- to 6-membered heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2, -NO2 and -CN.
39. The compound or salt of claim 38, wherein R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of optionally substituted C 3-6 Carbon ring.
40. The compound or salt of claim 39, wherein R 2 Selected from:
41. The compound or salt of claim 38, wherein R A is hydrogen; and R B Selected from: C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of 5-membered heterocyclic rings, the 5-membered heterocyclic rings are optionally substituted with one or more substituents independently selected from the group consisting of halogen, -OR16 、-N(R 16 )2, -NO2 and -CN.
42. The compound or salt of claim 41, wherein R 2 yes 43. The compound or salt of claim 29, wherein R A is hydrogen; and R B Selected from: optionally -N(R 16 )2 substituted C 1-6 Alkyl; wherein R 16 in each case selected from hydrogen, C 1-3 Alkyl and 3 to 6 membered heterocyclic ring, wherein each C 1-3 The alkyl and 3- to 6-membered heterocyclic rings are optionally substituted.
44. The compound or salt of claim 43, wherein R 2 Selected from:
45. The compound or salt of claim 29, wherein R A is hydrogen; and R B is selected from a 4- to 6-membered heterocyclic ring, the 4- to 6-membered heterocyclic ring being optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN.
46. The compound or salt of claim 45, wherein R A is hydrogen; and R B is selected from 4 to 6 membered saturated heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-N(R 16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2, -CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 16 、-N(R16 )2. -C(O)R 16 、-C(O)OR 16 , -NO2 and -CN.
47. The compound or salt of claim 46, wherein R A is hydrogen; and R B Selected from azetidine and pyrrolidine, each of which is optionally substituted with halogen, -OR 13 、-C(O)R 16 、-C(O)OR 16 replace.
48. The compound or salt of claim 47, wherein R 2 Selected from:
49. A compound or salt according to any one of claims 1 to 48, wherein is selected from 4 to 6 membered monocyclic heterocycles and 5 to 10 membered bicyclic fused heterocycles, each of which is optionally substituted with one or more substituents independently selected from: halogen, -OR 13 、-N(R 13 )2, -NO2, CN and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2, -NO2 and -CN.
50. The compound or salt of claim 49, wherein is selected from 4 to 6 membered monocyclic heterocyclic rings, any of which is optionally substituted by one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2 and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halogen and -OR 13 .
51. The compound or salt of claim 50, wherein is selected from azetidine, pyrrolidine, pyrazolidine, imidazolidine, piperidine, morpholine and piperazine, each of which is optionally substituted with one or more substituents independently selected from halogen, -OR 13 、-N(R 13 )2 and C 1-6 Alkyl, the C 1-6 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halogen and -OR 13 .
52. The compound or salt of claim 51, wherein is selected from pyrrolidine, piperidine, morpholine and piperazine, each of which is optionally substituted with one or more substituents selected from -OR 13 、-N(R 13 )2 and C 1-6 alkyl.
53. The compound or salt of claim 52, wherein Selected from:
54. The compound or salt of claim 51, wherein is selected from pyrrolidine, piperidine, morpholine and piperazine, each of which is optionally substituted with one or more substituents selected from C 1-3 Alkyl, the C 1-3 The alkyl group is optionally substituted with one or more substituents independently selected from the group consisting of: halogen and -OR 13 .
55. The compound or salt of claim 54, wherein Selected from:
56. The compound or salt of claim 49, wherein is selected from a 7- to 10-membered bicyclic heterocycle, any of which is optionally substituted by one or more substituents independently selected from C 1-6 Alkyl, optionally substituted with halogen, -OR 13 、-N(R 13 )2, -NO2 and -CN replaced.
57. The compound or salt of claim 56, wherein is selected from a 7- to 10-membered bicyclic heterocycle, any one of which is optionally replaced by C 1-3 Alkyl substitution.
58. The compound or salt of claim 57, wherein Selected from:
59. The compound or salt of claim 49, wherein is selected from a 5- to 8-membered spirocyclic heterocyclic ring, any of which is optionally substituted by one or more substituents independently selected from C 1-6 Alkyl, optionally substituted with halogen, -OR 13 、-N(R 13 )2, -NO2 and -CN replaced.
60. The compound or salt of claim 59, wherein yes 61. The compound or salt of claim 1, wherein formula (I) is selected from:
62. A pharmaceutical composition comprising a pharmaceutically acceptable salt and a compound according to any one of claims 1 to 61.
63. A method of modulating IL-17A in an individual in need thereof, comprising administering to the individual a compound or salt of any one of claims 1 to 61 or a pharmaceutical composition of claim 62.
64. A method of treating an inflammatory disease or condition comprising administering to a subject in need thereof a compound or salt of any one of claims 1 to 61 or a pharmaceutical composition of claim 62.
65. The method of claim 64, wherein the inflammatory disease or disorder is selected from plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, rheumatoid arthritis, palmoplantar psoriasis, spondyloarthritis, and non-infectious uveitis.
Citation Information
Patent Citations
IL-17 Ligands And Uses Thereof
US20200247785A1
Il-17a modulators and uses thereof
US20210101886A1
Enhancement of the efficacy of nifedipine by deuteration
US5846514A
Method of using deuterated calcium channel blockers
US6334997B1
Cited By
Novel compounds, compositions comprising the same and uses thereof
WO2026201079A1
